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Abstract
Five-year survival of oral cancer has remained relatively unchanged despite
advancements in treatment, mostly because diagnosis is often made at an advanced stage
of disease. The progression of dysplasia to oral cancer often follows a stepwise progression.
Histopathology is considered the ‘gold standard’ for diagnosing dysplasia and lesions at a
high risk of progression to oral cancer, but lends itself to subjectivity. The protein
biomarker, S100A7, in oral dysplasia and squamous cell carcinoma has shown some
predictive value for the transformation of dysplasia to cancer. Straticyte, a diagnostic test
utilizing S100A7 to predict the probability of progression of oral dysplasia to malignancy,
has recently been developed. Straticyte has never been used to predict progression of oral
dysplasia alone.
The objective of this study is to determine if S100A7 is a valuable biomarker in
predicting the progression of oral dysplasia. We also evaluated if Straticyte is a useful
tool to predict oral dysplasia progression.
Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from the
Tissue Archives of the Division of Oral Pathology at Western University. This study
included 29 cases of progressing oral dysplastic lesions, 17 cases of non-progressing oral
dysplastic lesions and 25 control cases of normal tissue. FFPE sections were stained for
S100A7, cell cycle-related protein cyclin D1, and -Catenin using standard
immunohistochemistry. Immunoreactivity of S100A7 was evaluated semi-quantitatively,
using an intensity and proportion scale, as well as quantitatively using an automated
scoring method (Straticyte) by image analysis. The data was analyzed to compare the
manual and automated scoring methods and to look for a correlation between S100A7
i

expression and progression of disease. Cyclin D1 and -catenin, other protein biomarkers,
were also analyzed qualitatively.
Mean manual score for the initial biopsy of the progressing, non-progressing and
control groups was 4.93, 4.83 and 3.52 respectively. The mean Straticyte score for the
initial biopsy of the progressing, non-progressing and control groups was 25.93, 34.91 and
30.65. Stepwise regression analysis showed the manual scoring method to be the best
predictor of lesions being non-progressing compared to controls (p=0.016). The same
analysis also showed the automated scoring method to be the best predictor of lesions being
progressing compared to non-progressing (p=0.078).
Neither the manual or the automated scoring methods proved to be significantly
superior to the other in predicting progressing of oral dysplasia. S100A7 did not prove to
be a useful biomarker in predicting progressing of oral dysplasia. More studies are needed
to determine both the usefulness of S100A7 and Straticyte for predicting progression of
oral dysplasia.

KEYWORDS: S100A7, oral dysplasia, oral cancer
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Summary for Lay Audience
Oral cancer is a disease that can lead to suffering and pre-mature death. The early
identification of oral cancer can be difficult and for this reason when oral cancer is detected
it is often large and has sometimes already spread to other parts of the body. In this study,
we evaluated if a protein, S100A7, can assist with detecting oral lesions (abnormal oral
tissue) that have a high likelihood of developing into oral cancer. To explore this, we used
a staining technique called immunohistochemistry (IHC), that allows for the stain to be
attached to the protein, S100A7, so that it can be visualized under a microscope. We
measured the amount of S100A7 both manually (manual method) and using a commercial
test called, Straticyte (automated method), that uses machine learning. We compared the
manual and automated methods to determine if either method was superior at measuring
the amount of S100A7 and predicting which lesions were high risk.
We determined that both methods showed some value; however, neither the manual
nor the automated method proved to be clearly superior at measuring S100A7 and
predicting high risk lesions.
We concluded that further studies are warranted to determine the value of S100A7
in identifying high risk lesions and in validating the usefulness of Straticyte.
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Chapter 1
1.0

Introduction

1.1 Oral Cancer
Cancers of the oral and pharyngeal cavity account for the 6th most common cancer
worldwide, 90% of which are squamous cell carcinomas (SCC) [1, 2]. SCCs can arise in
all parts of the upper aerodigestive tract including the lip, oral cavity, nasopharynx,
oropharynx, hypopharynx and larynx [3]. Of all the anatomical subsites, the oral cavity is
the most commonly involved site [3, 4]. Oral cancer is believed to be multi-factorial with
known risk factors (described below). The risk factors are similar for other cancers of the
head and neck, and most of which are preventable [1, 2]. There are several conditions that
are potentially malignant and consideration for these lesions must also be given.

1.1.1 Epidemiology/Prevalence of Oral SCC and Oral Potentially Malignant
Disorders
According to the World Health Organization (WHO), there is an estimated 529,000
new cases of oral cavity and oral pharyngeal cancer each year and an estimated 300,000
deaths per year [2]. Epidemiology of head and neck squamous cell carcinoma (HNSCC)
can be broken into two major categories: 1) HNSCC due to environmental exposures (ie.
tobacco, alcohol etc.); 2) HNSCC caused by human papilloma virus (HPV) [5].
Environmental HNSCC is typically seen in older patients compared to HPV-positive
HNSCCs, with the median age at diagnosis for environmental HNSCC and HPV-positive
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HNSCC being 65.6 and 57.8 years, respectively [6]. In addition, tobacco consumption
appears to be declining in developed countries but rising in underdeveloped countries [7].
Systematic reviews have estimated the worldwide prevalence of leukoplakia and
oral potentially malignant disorders (OPMD) to be 1.5 and 4.5%, respectively [7, 8]. Asian
followed by South American and Caribbean countries have the highest prevalence of
OPMD and this is felt to be due to habits relative to geographic location. The majority of
cases of OPMD are in individuals older than 50 years [7].

1.1.2 Risk Factors
Numerous risk factors have been identified for the development of OSCC [9, 10].
According to the WHO, excess alcohol consumption and tobacco use, including smokeless
tobacco account for approximately 90% of all oral cancer cases [11]. Men have shown to
have higher incidence and absolute mortality compared to women [11], but women have a
higher mortality rate, especially amongst non-smokers [12, 13]. Non-homogenous lesions
also carry an elevated risk relative to their homogenous counterparts [12].
Other well known risk factors for development of oral SCC (OSCC) are alcohol,
betel nut and HPV [9]. Although a strong association between tobacco consumption and
oral leukoplakia has long been realized, an evidence-based causal link is still missing [14].
A population-based study in Taiwan with over 2,000,000 participants showed that
participants who smoked and chewed betel quid had a 2.7 relative risk (RR) of developing
OPMD or OSCC. This study also showed that betel quid alone compared to smoking alone
had an increased risk (RR = 2.37) and that smoking compared to non-smoking had 1.17
RR. The merits of an effective screening program in identifying OPMD and early OSCC
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were also highlighted in this study [15]. It has been suggested that smoking cessation
provides a time-dependent benefit to smokers to reduce OPMD/OSCC, such that 10 years
after quitting smoking, the risk of developing OSCC is similar to a person that has never
smoked [16, 17]. Smokeless tobacco has also been shown to be a risk factor for OPMD
and OSCC [17, 18]. A meta-analysis from south Asia showed smokeless tobacco was
associated with an increased risk of OPMD (odds ratio (OR) = 15.5; 95% confidence
interval (CI) 9.9 - 24.2). Of the OPMDs, submucous fibrosis had the strongest association
(16-fold) and leukoplakia the weakest association (4-fold) with smokeless tobacco usage.
This study also showed a positive exposure-response relationship with risk increasing with
both duration and intensity of use. It was also found that females using smokeless tobacco
were at increased risk of developing OPMD relative to their male counterparts [18].
Alcohol is also a well-known independent risk factor for many cancers [10],
including OSCC, however, its associated risk with potentially premalignant oral epithelial
lesions (PPOEL)/OPMD is less understood [9].
It has been shown that combining risk factors can lead to a greater than additive
risk of developing disease. A large case-control study in India showed a multiplicative
interaction for smokeless tobacco and alcohol, resulting in a 24-fold increased risk of
developing OSCC [17]. This study also showed a relationship between the cancer site and
the risk factor: smokeless tobacco had the strongest association with oral cavity cancer,
smoked tobacco with pharyngeal and esophageal cancer and betel quid with oral cavity and
esophageal cancer. All 3 risk factors (chewing (tobacco & betel quid), alcohol and
smoking) analyzed were shown to increase the risk of oral, pharyngeal and esophageal
cancer [17].
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1.1.3 Oral Cancer as a Stepwise Disease
The development of oral cancer is thought to proceed in a gradual stepwise fashion
where degrees of dysplasia are reached prior to malignant transformation, and increasing
degrees of DNA damage have been correlated to this stepwise progression of cancer [1921]. Approximately 90% or more of oral cancers are OSCC. These cancers often start out
as potentially malignant lesions such as leukoplakia or erythroleukoplakia [22].
It is estimated that the prevalence of pre-malignant lesions is 2-3% worldwide (with
no significant difference between developed and developing countries) and the rate of
transformation of these pre-malignant lesions is estimated to be 2-5% per year [23, 24];
unfortunately, at present we do not have a reliable way of predicting which pre-malignant
lesions will undergo transformation to OSCC [25, 26]. Only about 50% of severe dysplasia,
30% of moderate dysplasia and less than 5% of mild dysplasia are believed to progress to
cancer [24].

1.1.4 Field Cancerization
The concept of field cancerization (or “field effect”) was first described by
Slaughter et al. in 1953 [27], which describes underlying genetic and pre-neoplastic
changes in the tissue that are not readily apparent clinically. This allows for oral cancer to
develop at multiple sites and lend itself to loco-regional recurrence or the presence of
‘secondary primary tumours’; the field lesion is believed to be of monoclonal origin and
has not yet developed the characteristics of invasive growth or metastatic behavior [28].
Field effects can often occur in tissue that has been deemed “normal” by
histopathological diagnosis, and not until more advanced molecular techniques are applied
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does the genetic alterations and field effect become apparent [29]. The study by Tabor et
al. showed that field effects were present in normal tissue as well as mild, moderate and
severe dysplasia. Genetic alterations were present in all of the moderate and severely
dysplastic lesions and about two-thirds of mild dysplastic lesions, suggesting that genetic
changes lead to progressive disease and more genetic alterations are expected with more
advanced disease [29].
It is believed that fields evolve from “patches” which are defined as “groups of cells
that share a common genotype contiguous at the moment” [30, 31]. These patches can be
considered a “clonal unit” with genetically altered daughter cells. Due to their genetic
alteration, these cells exhibit a growth potential advantage and expand to gradually become
a field, displacing normal cells and tissue laterally. The field can then be subject to multiple
other genetic hits, resulting in subclones and eventually, enough genetic mutations allow
for the cells to evolve into an invasive carcinoma [28].

1.1.5 Genetic Mutations Associated with Cancer Progression
The development of cancer occurs through the accumulation of genetic alterations
by way of genomic instability that confer succession of clonal expansions and the
acquisition of the hallmarks of cancer [32]. The hallmarks of cancer are: sustaining
proliferative signaling; evading growth suppressors; resisting cell death; replicative
immortality; angiogenesis; and invasion and metastasis as well as the emerging hallmarks,
which are evasion of the immune system and reprogramming of energy metabolism [32].
The accumulation of genetic mutations from normal epithelium to the development
of metastatic colorectal cancer was eloquently modeled by Fearon and Vogelstein in 1990.
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They showed that certain genetic alterations/mutations were responsible for the transition
of normal epithelium to various stages of adenoma and eventually, to a metastatic
carcinoma. More genetic alterations were observed with the progression to more severe
lesions. The authors believed that it was the accumulation of certain mutations that was
important rather than the order in which these mutations were accumulated [33]. Fearon
and Vogelstein’s model can be seen in Figure 1.1
Figure 1.1. Genetic changes associated with development of adenocarcinoma
of the colon. This figure was originally published in Cell. Fearon ER, Volgelstein, B. A
Genetic Model for Colorectal Tumorigenesis. 1990. 61: p. 759-767. This figure is being
reproduced for educational purposes only and not for commercial use. Figure is included
in the M. Sc. dissertation with attribution.

Genetic alterations initiating OSCC may result by chance, but most often are caused
by a lifetime of environmental exposures such as tobacco and alcohol [34]. At a basic level,
the development of OSCC is caused by an overexpression of oncogenes and a silencing of
tumour suppressor genes [33, 34]. The genetic alterations involved in the development and
progression of OSCC and head and neck cancers in general, are abundant, and new
pathways and interactions are being realized frequently. The development of OSCC is also
believed to occur from a clonal population that through a series of mutations has conferred
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a growth advantage over adjacent normal cells [21, 35]. It has been shown that genetic
alterations accumulate over time and this corresponds to the histopathological diagnosis as
a lesion progresses from pre-malignant to malignant state [20, 21]. The development of
clonal populations can occur long before the carcinoma is apparent; latency periods are
estimated to be in the order of many years [21]. These clonal populations are believed to
be able to migrate through the tissues which can explain how the entire aerodigestive tract
can be at risk [21].
In 1996, Califano et al. were the first to propose a model for oral carcinogenesis.
They analyzed 10 loci of commonly known mutations in carcinoma via polymerase chain
reaction (PCR)–based microsatellite marker analysis. They found that certain genetic
alterations were present at certain histopathologic stages and formed the initial and
preliminary model for oral carcinogenesis. In their work, they acknowledged that there will
undoubtedly be more genetic alterations accounted for in the future [20]. The Califano and
Sidransky et al. model is shown in Figure 1.2.
Figure 1.2. Initial model for oral carcinogenesis. This figure was originally published in
Cancer Research. Califano J, Riet PVD, Westra W, Nawroz H, Clayman G, Piantadosi S,
Corio R, Lee D, Greenberg B, Koch W, Sidransky D, Genetic progression model for head
and neck cancer: implications for field cancerization. 1996. 56(11): p. 2488-2492. This
figure is being reproduced for educational purposes only and not for commercial use.
Figure is included in the M. Sc. dissertation with attribution.
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A more contemporary and simplified model depicting some of the molecular events
required for the transformation from normal tissue to oral cancer presented by Nikitakis et
al. is shown in Figure 1.3. These events do not need to occur in a linear fashion, nor are all
of them required in order for cancer to develop [36].
Figure 1.3. Molecular events associated with oral cancer transformation. This figure
was originally published in Oral Surg Oral Med Oral Path Oral Radiol. Nikitakis NG,
Pentenero, M., Georgaki M, Poh CF, Peterson DE, Edwards P, Lingen M, Sauk JJ.
Molecular markers associated with development and progression of potentially
premalignant oral epithelial lesions: Current knowledge and future implications. 2018.
125: p. 650-669. This figure is being reproduced for educational purposes only and not for
commercial use. Figure is included in the M. Sc. dissertation with attribution.

Tumour suppressors are important for regulating the cell cycle, DNA repair
mechanisms and programmed cell death. If tumour suppressor genes (TSG) are not
functional, cell growth can go unchecked and this can lead to the development of cancers
[34]. TP53 is one of the earliest identified TSGs and encodes for the protein p53. The
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silencing of p53 has been observed in premalignant head and neck lesions [37], HNSCC
[38] and in numerous other cancers [39]. In a prospective, multi-center study looking at
survival of HNSCC patients with and without TP53 mutations in their tumours, the authors
found that patients with any TP53 mutation had decreased overall survival (hazard ratio
for death, 1.4; 95% CI 1.1 – 1.8; P = 0.009) compared to those without TP53 mutations.
They also found that disruptive mutations, with more protein disturbance, were particularly
impactful on survival compared to un-mutated TP53 (hazard ratio 1.7; 95% CI, 1.3 – 2.4;
P < 0.001); non-disruptive mutations had no association with decreased survival [40].
Oncogenes in HNSCC have also been extensively studied. Epidermal growth factor
receptor (EGFR) works through the tyrosine kinase cascade and has shown to be
overexpressed in many HNSCC tumours, especially those that are well differentiated [41].
Matrix metalloproteinases (MMPs) are a family of matrix-remodeling enzymes believed
to be involved with many cellular functions such as migration, adhesion and proliferation
[34]. Various MMPs have been implicated in cancer development. MMP-7 overexpression
was associated with early stage (I & II) OSCCs, and it was hypothesized that early-stage
MMP-7 expression is attributed to its anti-angiogenic activity [42]. In another study of 54
patients with HNSCC, MMP-9 overexpression significantly correlated to lymph node
metastasis (P < 0.001) [43].
Other alterations that have been studied in the development OSCC include loss of
heterozygosity (LOH), telomerase activity, chromosomal aneuploidy and microsatellite
instability. Mitochondrial alteration and epigenetic changes, such as hypermethylation are
also being implicated in cancer progression [35, 36]. A large systematic review found
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LOH, survivin, MMP-9 and DNA content (non-diploid) to be the strongest predictors for
malignant transformation, among biomarkers tested [44].

1.1.6 Treatment and Prognosis of OSCC
One of the greatest challenges in the treatment of OSCC can be in its detection. Precancerous lesions are often asymptomatic and can be difficult to detect on routine clinical
exam; for these reasons, oral and oropharyngeal cancer are often not diagnosed until a later
stage [45]. Early detection is crucial because it is directly correlated to stage de-escalation
at initial presentation and impacts the 5-year survival [46]. Stage at diagnosis has been
regarded as the most important prognostic indicator of OSCC [47]. Late stage of initial
diagnosis can to some extent, be the result of limited biomarkers to detect early disease.
Despite advances in treatment modalities over the years, the relative 5-year survival
remains around 50% and appears to be highest for those treated with either surgery alone,
or in conjunction with radiation [48]. Currently, the mainstay of treatment for OSCC is
surgery. More advanced disease is generally treated with multi-modal therapy including
adjuvant radiotherapy with or without chemotherapy in addition to surgery [3].
For OSCC, surgery will be employed if there is curative intent or in some cases as
surgical salvage. For curative intent, the goals of surgery are to remove the entire tumour
while preserving the patients function and maintaining acceptable cosmesis [49].
Surgery on the primary tumour can be broken down into ablative surgery (removal
of the tumour) and reconstructive surgery (restoring the defect) [3]. Reconstructive surgery
can be performed by either primary closure, loco-regional flaps or free tissue transfer [3].
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In addition to resection of the primary tumour in the oral cavity, surgery is also used
to perform a neck dissection in select cases. Neck dissections can be used to remove gross
nodal disease, or be performed prophylactically/electively if occult disease is suspected [3,
49].
In a retrospective study by Quinlan et al, 289 patients with OSCC were analyzed
over a 12-year period. Ninety-three percent underwent surgical neck dissection and of those,
66% had nodal involvement and 51% had extracapsular spread, indicating more advanced
disease. Despite this group of patients being treated with a combination of surgery and
either chemotherapy and radiation or both, the 5-year loco-regional control and overall
survival was still only 76% and 51% respectively [50]. This study emphasizes the impact
advanced disease has on tumour recurrence and mortality.
Another study by Dillon et al. looked at 20 patients with oral cavity squamous cell
carcinoma (OCSCC) of the buccal mucosa whom had no clinically identifiable lymph node
involvement (N0) [51]. Of these 20 patients, 15 (75%) patients underwent elective neck
dissection (END). Of the 5 patients who did not undergo an END, all of them (100%) had
loco-regional recurrence and one (20%) had distant metastasis; compared to only 5 (33%)
with loco-regional recurrence and 1 (7%) with distant metastasis among the 15 who did
undergo END. Additionally, the 2 and 5-year survival rates for N0 patients without END
was 80% and 40% respectively, compared to 93% and 87% for N0 patients who did
undergo END. Although the sample size was small, these findings not only suggest the
benefits of performing END in patients without clinically identifiable neck disease, but
also speak to the ability of cancer to evade detection [51].
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Chemotherapy is also used in OSCC. At present the cornerstone of chemotherapy
treatment is cisplatin, however, other agents such as 5-fluorouracil and docetaxel are also
used. Chemotherapy has various uses in HNSCC which include: definitive primary
treatment of locally advanced HNSCC in conjunction with radiation; adjuvant treatment
with post-operative radiation; induction chemotherapy; and treatment of metastatic or
recurrent disease [5]. In addition to the traditional chemotherapies mentioned, novel
immunotherapies such as Cetuximab are also being used with favorable results [5, 52].
The other main modality of OSCC treatment is radiotherapy (RT). RT can be used
as primary, adjunctive or salvage therapy. The prescription will vary depend on many
factors and depending on if the intention is primary, adjunctive or salvage treatment, but
in general, OSCC will generally receive > 60 Gy [53].
Radiation technology has improved to deliver the RT with precision using
intensity-modulated radiotherapy (IMRT), which has reduced complications [53]. Despite
this, RT still has an abundance of complications associated with it. These complications
include

but

are

not

limited

to:

caries,

periodontitis,

thickened

mucosal

secretions/xerostomia, mucositis, soft tissue fibrosis, oropharyngeal candidiasis,
osteoradionecrosis (ORN), pain and taste dysfunction [54], all of which can adversely
affect quality of life.
Osteoradionecrosis is known to be caused by total dosage > 60 Gy, with the
mandible being at greater risk than the maxilla. There is also some evidence that prior
mandibular surgery elevates the risk of developing ORN in the mandible [53].
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Despite advances in the treatment of OSCC, there is still considerable morbidity
and mortality. More advanced disease requires more extensive treatment which leads to
greater morbidity.

1.2 Pre-cancer
1.2.1 Oral Potentially Malignant Disorders (OPMD)/Potentially Pre-Malignant Oral
Epithelial Lesions (PPOELs)
Lesions that have been known to potentially give rise to OSCC have historically
been described as “premalignant”, however, because only a portion of these lesions will
progress to OSCC, the more appropriate terminology is to describe these lesions as
“potentially pre-malignant”. For this reason, the terms “oral potentially malignant disorders
(OPMD)” or “potentially pre-malignant oral epithelial lesion (PPOEL)” are now preferred
[13, 55, 56].
The term OPMD is used in the latest WHO classification to encompass all
potentially malignant lesions and disorders [22]. OPMD is defined by the WHO as,
“clinical presentations that carry a risk of cancer development in the oral cavity, whether
in a clinical definable precursor lesion or in clinically normal oral mucosa” [22]. The term
PPOEL has recently been used as a broad term to include both histologic and clinical
lesions that may progress to malignancy [56].
The lesions/disorders commonly referred to as OPMD/PPOEL are: leukoplakia,
erythroplakia, erythroleukoplakia, oral lichen planus, oral submucous fibrosis (OSF),
actinic chelitis, palatal lesions of reverse smoking, discoid lupus erythematous, oral
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dysplasia, chronic candidiasis, smokeless tobacco keratosis, syphilitic glossitis and some
inherited disorders such as dyskeratosis congenita and Fanconi anemia [13, 22, 56].

1.2.2 Oral Epithelial Hyperplasia/Dysplasia
Hyperplasia – is an increase in cell number with regular stratification/architecture and no
cellular atypia (variations in size or shape of keratinocytes) [26].
Dysplasia – architectural disturbance accompanied by cellular atypia [26].
Features of abnormal architecture and cellular atypia are shown in Table 1.1:
Table 1.1. Architectural and cytological features associated with oral dysplasia. This
table was originally produced in Journal of Oral Pathology and Medicine.
Warnakulasuriya S, Reibel J, Bouqout J, Dabelsteen E. Oral epithelial dysplasia
classification systems: predictive value, utility, weaknesses and scope for improvement.
Journal of Oral Pathology and Medicine, 2008. 37(3): p. 127-133. The table is being
reproduced for educational purposes only and not for any commercial use. Table is
included in the M. Sc. Dissertation with attribution.

In general, the grade of dysplasia corresponds to the number and prominence of
these features.
Mild Dysplasia – minimal cytological atypia and architectural disturbance, limited to lower
1/3 of epithelium [26].
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Moderate Dysplasia – architectural disturbance extending into middle 1/3 of epithelium.
Consideration is then given to cytological atypia, in which marked atypia is upgraded to
severe dysplasia and minimal atypia downgraded to mild dysplasia, despite having
architectural disturbance extending into the middle 1/3 of epithelium [26].
Severe Dysplasia – architectural disturbance extending into the upper 1/3 of epithelium
[26].

1.2.3 Risk of Progression of OPMD/PPOELs
OPMD/PPOELs may have an increased risk of malignant transformation, but the
difficulty lies in predicting which of these lesions will progress and which will not. There
are, however, certain clinical characteristics that have shown value in predicting the risk of
progression. Some of these main clinical characteristics are: size of lesion,
texture/color/clinical appearance, site, sex and age of the patient [13].
For OPMD/PPOELs, the anatomic site in the oral cavity appears to be associated
with risk of progression, but this is also correlated to the geographic region globally and
regional lifestyle behaviours. For example, in South Asia where Areca Nut (Betel Quid) is
frequently consumed, the buccal mucosa is associated with the highest progression. In
reverse smokers, the palate is often the highest risk site and in the developed world, where
smoking and alcohol are the most predominant habits, the floor of mouth and lateral tongue
sites are associated with the highest risk of progression [3, 13]. In a retrospective analysis
done on 216 patients in Australia, the floor of mouth and lateral tongue were shown to have
an increased risk of being dysplastic or malignant relative to other anatomic sites (OR 2.6,
P = 0.005) [57]. A retrospective study of 630 patients from London and Bristol, UK
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showed dysplastic lesions to be present in the tongue or floor of mouth 41.5% of the time.
Although not statistically significant, these sites were also more likely to have severe
dysplasia than other anatomical sites [58]. The ventral/lateral tongue and floor of mouth
may be at greater risk for developing more severe disease because of pooled saliva in
tobacco users. In patients with oral cancer, increased concentrations of nitrites have been
found in the saliva of tobacco users [59, 60].
The clinical appearance has also been shown to be predictive of transformation,
with non-homogenous lesions in color and texture being at greater risk for progression,
than their homogenous counterparts [12, 57]. Dost et al. found that non-homogenous
lesions had a significantly increased risk of being dysplastic relative to homogenous lesions
(OR 4.4, P < 0.005). The authors concluded that any red and white lesion be considered
high risk and that, because clinical appearance is used to assess long term surveillance of
a lesion, it is the most reliable and important feature for determining additional surgical
intervention [57]. Many other studies have also supported this finding that nonhomogeneous lesions are at greater risk for cancer progression than homogeneous lesions
[12, 61].
Age has also been shown to be a predictor of malignant transformation, with older
age increasing risk [62]. The exact transformation rate of oral leukoplakia is unknown but
a systematic review of observational studies found it to be on average 3.8% per year, but
when evaluated further, the annual transformation rate of homogeneous lesions was 3%,
while the transformation rate of non-homogeneous lesions was 14.5% (P = 0.001) [62].
This same study also showed that oral lesions that are going to transform to malignancy
will do so most often within the first 5 years after initial presentation [62]. A study by Jaber
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et al. showed that the average age of a patient with an oral dysplastic lesion was 55 years
old. In this same study, they also analyzed a younger cohort of patients (< 35 years old)
because it has been suggested that younger patients exhibit more aggressive disease [63],
however, Jaber et al. found no significant difference in the grade of dysplasia at diagnosis
between younger and older patients [58].
In studies that have evaluated the relationship between sex and malignant
transformation, although it is more common for males to have a lesion, proportionately,
lesions in females are more likely to progress to malignancy [13]. Unfortunately, the
reasons for this are still largely unknown [13, 62]. In a study of 166 patients with
leukoplakia from the Netherlands, 16 out of 90 female and 4 out of 76 male patients had
malignant transformation at a median follow-up of 32 months (P < 0.025). Interestingly,
female non-smokers were also at greater risk for malignant transformation than their
smoker counterparts (P < 0.05) [12].
Size of lesion is another predictor of malignant transformation. A retrospective
study by Holmstrup et al. looked at 269 patients and found that lesions greater than 200
mm2 have an odds ratio for cancer progression of 5.4 relative to lesions smaller than that
200 mm2 [61].
In a longitudinal observational study at a tertiary oral dysplasia clinic in Liverpool,
Ho et al. evaluated 92 patients with oral epithelial dysplasia for a median follow-up period
of 48 months. The investigators estimated a 22% transformation rate at 5 years after initial
diagnosis. The significant clinical determinants they found to be predictive of malignant
transformation were: 1) non-smoking status; 2) non-homogeneous appearance; and 3) size
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greater than 200 mm2. Of borderline significance was high-grade dysplasia. Found to be
not predictive were gender, age, number of lesions and alcohol consumption [64].

1.2.4 Diagnosis
Currently, for a final diagnosis to be established, histopathology with tissue biopsy
should be performed. Histopathology remains the gold standard for diagnosis of oral
epithelial dysplasia, other PPOELs and OSCC. For oral dysplasia, the histopathologic
grade is used to determine the risk for malignant potential [22]. Unfortunately,
histopathologic diagnosis of oral dysplasia is subjective and associated with limitations
such as intra- and inter-observer variations in diagnosis [22, 26, 65-67]. This has led some
to recommend that observer bias could be reduced if calibration exercises are performed
amongst pathologists [68].
An increasing grade of dysplasia from mild to severe, generally has been associated
with a higher rate of malignant transformation [69, 70]; however, the difficulty lies in
predicting which dysplastic lesions will progress to cancer as many have been shown to
remain static or regress, whereas some non-dysplastic lesions may become malignant [26,
67]. Because intra- and inter-observer variability complicates the diagnosis of oral
dysplasia, a binary grading system based on 4 architectural and 4 cytological features with
the addition of smoking and alcohol consumption has been proposed, and shown to
improve observer correlation and prognostication [22]. This binary system is shown in
Table 1.2.
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Table 1.2. Grading Scheme for Oral Epithelial Dysplasia.
WHO dysplasia grade:
Mild dysplasia

Binary System:

Low-grade dysplasia

Moderate dysplasia
High-grade dysplasia
Severe dysplasia
Adapted from the WHO classification of head and neck tumours, 2017 [22].
In a study by Kujan et al., a binary system was utilized (high- and low-grade
dysplasia) and the authors showed that 80% of high-grade lesions and 15% of low-grade
lesions transformed to carcinoma. The binary system was found to have a sensitivity and
specificity of 85% and 80% respectively. The accuracy of the test was 82% [71] and the
authors concluded that a binary system was useful for predicting malignant transformation
and accurately differentiating the moderate dysplasia group [71].
In a follow-up study by Nankivell et al., the same binary system was used in a
retrospective cohort study with the aim of validating the work of Kujan et al. The authors
found that although the binary system had improved inter-rater reproducibility compared
to the standard (non-binary) WHO grading system, the prognostic ability of the binary
system was the same. The binary system in this study was not useful at accurately
predicting which moderate dysplasia cases should be placed into low- or high-grade lesion
categories. The authors also propose that using 4 architectural and 4 cytological features is
the optimal cutoff for capturing the most malignant transformations, rather than 4
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architectural and 5 cytological features which the authors claimed was the current standard
at the time of their study [72].
Another important consideration is that for a biopsy to be performed, the lesion
must initially be observed clinically. It has been shown that oral cancer is detected more
often and at a lower stage in a dental office relative to a medical office. The same study
showed that lesions identified at a dental office were most often in asymptomatic patients,
compared to lesions identified at a medical office that were more often symptomatic [47].
Lesions that are symptomatic or persistently painful will often be more advanced disease.
This can lead to a higher stage oral cancer at initial diagnosis and higher mortality rates
[22, 47].
The clinical exam is one of the first steps in the diagnostic pathway and the
importance of performing a thorough exam should not be understated, however, the
effectiveness and reliability of the clinical exam has been questioned [73]. Complicating
the clinical exam is there is some evidence that “normal” appearing tissue can harbor premalignant or malignant changes when it is viewed histologically [74]. This phenomenon is
possible due to the field effect previously discussed [74].

1.2.5 Treatment and Prognosis of Oral Dysplasia
Cancer development is generally believed to be a stepwise progression, and as a
result, identifying early precursor lesions, such as oral epithelial dysplasia and intervening
before cancer has progressed is ideal [22, 75]. For the treatment of oral dysplasia there are
no unanimously agreed upon guidelines as no randomized controlled trials (RCTs) have
been conducted, making this topic an area of controversy [75]. The main difficultly is with
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predicting which pre-malignant lesions will go on to develop cancer and the impact of
interventions on mitigating this risk is still uncertain. In short, there is no consensus on
treatment or even follow-up for patients with oral epithelial dysplasia [76].
Numerous interventions for oral epithelial dysplasia have been tried; these include
surgical, medical and complementary. Medical and complementary interventions that have
been attempted, include: Vitamin A and retinoids; beta carotene and carotenoids; nonsteroidal anti-inflammatory drugs (ie. ketorolac and celecoxib); green tea extracts; EGFR
inhibitors/antagonists, p53 modulators, bleomycin and Bowman-Birk inhibitor; however,
these have either been experimental, ineffective or poorly tolerated in the treatment or
prevention of oral dysplasia [77-79]. In 2016, a Cochrane systematic review found no
substantial evidence to support the use of medical and complementary therapies. This
report also highlighted that, in general, there are few high quality studies on the treatment
of oral dysplasia and there are no RCTs that have evaluated the impact of surgical
intervention on dysplasia progression [77]. As it stands, oral epithelial dysplasia is usually
treated with surgery or active surveillance. Surgery primarily includes excision with a
scalpel, laser or cryosurgery [79].
Mehanna et al. in a systematic review and meta-analysis of observational cohort
and case-control studies of 992 patients, found the mean malignant transformation rate to
be 12.1% over an average of 4.3 years. The mild and moderate oral dysplasia transformed
at a much lower rate of 10.3%, compared to severe dysplasia and carcinoma in situ that
transformed at 24.1%. This meta-analysis was also supportive of surgical excision as an
intervention, with malignant transformation occurring in 14.6% of the observation group
and 5.4% of the surgical group [70].
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However, not all studies are supportive of surgery for the prevention of malignant
transformation. A retrospective study performed by Homlstrup et al., examined two groups
of patients: surgical intervention (ie. complete excision) vs. surveillance and found that
surgery did not appear to have a protective role in malignant transformation [61]. The
authors of this study suggested that this result could be due to field cancerization.
Although there are no specific guidelines for how to best manage oral epithelial
dysplasia, the main treatments are surgery and surveillance [80]. The Liverpool protocol is
a

well-known

algorithm

for

managing

oral

epithelial

dysplasia

and

most

surgeons/clinicians around the world follow some construct of similarity [75]. The
Liverpool algorithm is shown in Figure 1.4.
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Figure 1.4. The Liverpool management algorithm for oral epithelial dysplasia. This
table was originally produced in Oral Oncology. Field EA, McCarthy C, Ho MW, Rajlawat
BP, Holt D, Rogers SN, Triantafyllou A, The management of oral epithelial dysplasia: The
Liverpool algorithm. Oral Oncol, 2015. 51: p. 883-887. This figure is being reproduced
for educational purposes only and not for any commercial use. Figure is included in the M.
Sc. dissertation with attribution.

In the Liverpool protocol, if it is amenable to the patient’s function, all moderate
and severe dysplasia, carcinoma in situ (CIS) and mild dysplasia that have predictive risk
factors, will undergo wide local excision. The only group that can go into routine
monitoring are the mild dysplasia without predictive risk factors. In areas where the lesions
are deemed to be too large or involving vital structures, lesions will sometimes be observed
and re-biopsied if there is any worrisome clinical change. Lifetime follow-up with the
multi-disciplinary team/oral dysplasia clinic is implemented for moderate dysplasia, severe
dysplasia, CIS and mild dysplasia with predictive risk factors. Mild dysplasia without
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predictive risk factors will be followed for 5 years and then may be discharged back to the
general dentist for ongoing follow-up [75].
Another proposed algorithm from Awadallah et al. for the management of oral
epithelial dysplasia is shown in Figure 1.5.
Figure 1.5. Awadallah Management Algorithm for Oral Epithelial Dysplasia. This
table was originally produced in Oral Surg Oral Med Oral Pathol Oral Radiol. Awadallah
M, Idle M, Patel K, Kademani D. Management update of potentially pre-malignant oral
epithelial lesions. 2018. 125(6): p. 628-636. This figure is being reproduced for educational
purposes only and not for any commercial use. Figure is included in the M. Sc. dissertation
with attribution.

The Awadallah algorithm is like the Liverpool algorithm, with the main differences
being that although both favor lifelong follow-up for all dysplastic lesions, the Awadallah
algorithm has follow-up at more frequent intervals. Specific mention to the size of the
clinical margin of normal tissue for moderate and severe oral dysplasia is also mentioned
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in the Awadallah algorithm. Despite these minor differences, both algorithms emphasize
the importance of regular and routine surveillance and surgical excision for any dysplastic
lesion that is even remotely worrisome [56, 75].
In a study evaluating the value of having a multidisciplinary center monitor and
treat oral dysplasia, Ho et al. showed that cancers at a multidisciplinary center were
diagnosed at an earlier stage allowing for less extensive interventions and favorable longterm outcomes. The study had 91 patients being followed for oral dysplasia, of which 23
(25%) developed malignancy, with stage 1 disease. Twenty-one were treated with wide
local excision, 2 were treated with ablation and reconstruction and 2 were treated with
adjuvant radiotherapy. With a median follow-up of 24 months, overall survival was 96%
and disease-free survival was 100%. Three patients had local recurrence, 1 had regional
recurrence and 5 patients had secondary primary tumours [81]. This study favors oral
epithelial dysplasia being monitored in a specialist/multidisciplinary clinic.

1.2.6 Molecular Markers Associated with Development and Progression of PPOELs
Numerous molecular markers have been evaluated in PPOELs. Some of the main
markers that have been evaluated are: DNA aneuploidy; loss of heterozygosity (LOH); cell
cycle, proliferation and apoptosis-related molecules such as Ki-67, cyclin D1, p16 and p53;
telomeres and telomerases involved with cellular immortality; vascular endothelial growth
factor A (VEGF-A) for angiogenesis; cell adhesion related molecules such as E-cadherin
and -catenin; degradative enzymes such as MMPs; signaling pathway molecules such as
EGFR; epigenetics such as histone modification,

micro RNAs (miRNAs) and

hypermethylation; cancer stem cells; DNA damage response biomarkers and S100A7 [36].
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1.3 Biomarkers Associated with Oral Dysplasia
1.3.1 S100A7
In 1991, S100A7 was originally identified to be up-regulated in psoriatic
keratinocytes and it was given the name “Psoriasin” [82]. At this time, it was postulated to
be involved in inflammatory cascades [82] and has since been discovered to be involved
in chemotaxis of neutrophils and helper T cells [83]. S100A7 is an 11.4-kDa Ca2+ binding
protein made up of 101 amino acids and encoded by S100A7 gene on the epidermal
differentiation complex on chromosome 1q21 [36, 82-88]. It has two Ca2+ binding sites of
the helix-loop-helix (EF – hand type) conformation [89]. This protein is involved in many
inflammatory processes [84] such as systemic lupus erythematous (SLE) [90] and atopic
dermatitis [91]. S100A7 is found in both the nucleus and cytoplasm and is involved in
regulating many cellular processes, such as proliferation and differentiation [84]. S100A7
expression has been observed to be predominantly confined to the epidermis of epithelial
tissue and in psoriatic patients, it was observed to be mostly in the mid to upper zones of
the epidermis [92]. In normal epithelium, S100A7 expression is also greatest in the spinous
layer, where it is found mostly on the cytoplasmic membrane, but can also be found in
small amounts in the cytosol of the basal layer [93]. Higher expression in the upper, welldifferentiated epidermal layers, rather than the basal layer, suggests that S100A7 has more
of a role in cellular differentiation than it does in proliferation [93, 94]. The expression of
S100A7 has also been found to be higher in CIS, keratoacanthoma and differentiated SCC
than it is in undifferentiated SCC and undifferentiated basalioma, supporting that S100A7
is involved in keratinocyte differentiation [95].
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S100A7 has been identified in numerous cancers, such as SCC of bladder [96] and
lung [97], breast carcinoma [98] and OSCC [99]. Studies showing higher S100A7
expression in ductal carcinoma in situ (DCIS) than the adjacent invasive breast cancer
suggest a role of S100A7 in early carcinogenesis [98]. S100A7 has also been speculated to
have a protective function against cancer cell invasion [100]. The S100A7 gene has been
shown to control proliferation and invasive potential of breast cancers through its activation
of nuclear factor-kappa B (NF-), VEGF and MMP-9 [101]. In addition, S100A7 in
breast cancer increases reactive oxygen species (ROS) and VEGF in a paracrine manner
through the receptor for advanced glycation end products (RAGE), leading to angiogenesis
[102]. Evidence also shows that S100A7 may possess differential activities; through the
-Catenin/T-cell factor 4 pathway, S100A7 enhances tumourigenesis in estrogen receptornegative cells but inhibits tumourigenesis in estrogen receptor-positive cells [89].
S100A7 is known to have effects both intra and extracellularly; extracellularly
S100A7 interacts with matrix and induces the secretion of soluble factors involved with
immune cell recruitment, tumour cell migration/invasion, matrix remodeling and
angiogenesis [103]. The use of monoclonal antibodies against S100A7 has shown
reduction in tumour growth and inhibition of invasion [103].
In HNSCC, S100A7 was originally identified in 2008 by proteomic analysis, in
which differential expression of S100A7 was found in patients with HNSCC compared to
healthy controls [104]. S100A7 is thought to play a role in local tumour progression by
activating the mitogen-activated protein kinase (MAPK) signaling pathway via the RAB2A
pathway in OSCC [99]. In another study, S100A7 was responsible for anoikis resistance
and tumourigenesis in oral cancer cells. This same study showed high expression of
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S100A7 measured in the saliva of individuals with HNSCC and absence of S100A7 in
saliva from healthy controls, prompting the authors to suggest that S100A7 may have
utility in both detection of early cancers and in long-term surveillance for individuals with
prior disease [105].
A retrospective cohort study evaluated the utility of 3 protein biomarkers to predict
recurrence-free survival of OSCC patients; one of these biomarkers was S100A7. Based
on the algorithm, a biomarker signature score was generated which stratified the OSCC
patients into two groups: high and low risk for recurrence. There were two separate
populations the evaluators examined, a population from India and one from Canada. In the
Indian population, the disease-free survival at 3 years for the high- and low-risk groups
was 30% and 71%, respectively, showing good utility of the biomarkers for predicting
recurrence. In the Canadian population, the disease-free survival at 3 years for the highand low-risk groups was 32% and 50%, respectively [106]. Although the algorithm
performed better at predicting recurrence in the Indian population, this study still shows
that S100A7 may have some clinical utility in predicting recurrence risk. Multi-center,
prospective studies would be helpful in validating this.
S100A7 expression has been evaluated in both PPOELs and HNSCC. In 2010,
Tripathi et al. discovered overexpression of S100A7 in oral dysplasia/hyperplasia and
HNSCC as compared to normal tissue [107]. Through correlation studies, they also found
nuclear accumulation of S100A7 to be a positive predictor of poor prognosis in HNSCC
patients [107]. This study also detected S100A7 overexpression in squamous cell
hyperplasia with no evidence of dysplasia [107]. In 2014, Kaur et al. evaluated the
expression of S100A7 in patients with oral lesions having histopathological evidence of
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dysplasia and a known clinical outcome [108]. They found that most cases of dysplasia
that progressed to malignancy exhibited S100A7 overexpression. Specifically, cytoplasmic
S100A7 was shown to be the most significant risk factor for cancer development, having a
positive predictive value (PPV) of 75.6% and a negative predictive value (NPV) of 78.5%
[108].

1.3.2 Beta-catenin
-catenin was first identified in the 1980’s as being associated with Uvumorulin
(E-Cadherin), a Ca2+ -dependent cell adhesion molecule and integral membrane protein
[109]. -catenin (95 kDa) is an oncogene that is the central player in the canonical Wnt
signaling cascade [110, 111]. The Wnt--catenin pathway is involved in stem cell
maintenance, cell survival, migration, motility, proliferation and fate determination during
development [112]. -catenin is a cytoplasmic protein that in the absence of Wnt signaling
will be targeted for degradation through the ubiquitin-proteasome pathway via its
association with the adenomatous polyposis coli (APC) protein and glycogen synthase
kinase 3 (GSK 3) complex. However, in the presence of Wnt signaling, -catenin
translocates to the nucleus where it activates target genes associated with cancer
development and progression [110, 113].
-catenin also exists in a cadherin-bound form and couples the cadherin proteins to
cytoskeletal proteins [110, 111]. Loss of the -catenin-cadherin adhesion complex can lead
to increased cytoplasmic levels of -catenin which can enhance oncogenic activity of catenin [112]. -catenin was shown to be downregulated in esophageal, colon and stomach
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cancers relative to normal controls, suggesting that the -catenin/E-cadherin complex is
important for preventing cellular invasion and metastasis [111].
In a study evaluating the expression of the cadherin-catenin complex in oral
dysplasia and OSCC, loss of the cadherin-catenin complex was found to be a late event in
tumourigenesis and was associated with invasion, metastasis and loss of differentiation
[114].
One study has shown -catenin to have a reciprocal relationship to S100A7, such
that S100A7 is believed to be a negative modulator of -catenin, by targeting it for
degradation via a non-canonical mechanism that is independent from GSK 3 mediated
phosphorylation. In the same study, the overexpression of -catenin was also shown to
inhibit S100A7 [94]. The authors suggested that Wnt--catenin is the ‘master-switch’ for
transitioning from cellular differentiation to proliferation and that S100A7 functions as a
tumour suppressor to prevent this through its negative modulation of -catenin [94].

1.3.3 Cyclin D1
Cyclin D1 is a member of a family of proteins involved in cell cycle progression
[115]. Cyclin D1 is encoded by CCND 1, located on chromosome 11q13 and is principally
responsible for promoting the transition between the G1-S phase of the cell cycle [116].
In relation with its catalytic partners, such as CDK 4 and CDK 6 (cyclin dependent kinase
4 and 6), cyclin D1 promotes progression through the restriction point of the cell cycle
[117, 118]. Progression through the restriction point of the cell cycle is thought to be caused
by the effect of cyclin D1 and its associated kinases on retinoblastoma protein (pRB), a
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tumour suppressor protein. Cyclin D1 and CDK 4 and CDK6, phosphorylate pRB,
removing its suppressive effect on the cell cycle [119].
Cyclin D1 has been linked to many oncogenic functions such as proliferation, cell
growth, mitochondrial modulation, DNA damage response, migration and cellular
differentiation [116]. Cyclin D1 overexpression is associated with larger tumour size,
advanced clinical stage, lymph node involvement, poor differentiation and lack of response
to treatment, all of which impart a poor prognosis [116, 120].
Cyclin D1 has been evaluated in oral epithelial dysplasia as well as OSCC. A study
by Rousseau et al. found similar levels of cyclin D1 protein in all grades of dysplasia and
OSCC [121]. The authors also concluded that approximately 10% of epithelial cells in
normal tissue produce cyclin D1 and its expression is confined to the basal and parabasal
layers in normal tissue but can be found higher up in the epithelium in dysplasia [121].
Another study by Shintani et al. found cyclin D1 to be highly expressed in OSCC,
but not expressed in dysplastic lesions, and instead, cyclin E was found to be overexpressed
in dysplastic lesions. These authors concluded that cyclin D1 may play a role once OSCC
has been established, but cyclin E is more important in the pre-cancerous state [122].
Two recent systematic reviews and meta-analysis evaluating the utility of protein
biomarkers in predicting OSCC suggest that cyclin D1 may be a useful biomarker [123,
124]. Both reviews reported that the quality of studies is low and that more high quality,
multi-center research is still required to validate the utility of cyclin D1 [123, 124].
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1.4 Straticyte
1.4.1 Straticyte Test to Predict Oral Dysplasia Progression
S100A7 expression has previously been associated with HNSCC [104] and
suggested to be associated with a poor prognosis in HNSCC [107]. S100A7 overexpression
has been suggested to be associated with oral dysplasia progression to malignancy [108].
Straticyte is a diagnostic test, developed by Proteocyte AI (Toronto, Ontario,
Canada), that quantifies the expression of S100A7, to predict the risk of transformation
from pre-cancerous lesions to invasive malignancy [125]. Hwang et al. have evaluated
Straticyte and claim it classifies pre-cancerous lesions more accurately than
histopathological grading for risk of progression to cancer over a 5-year period [25].
However, a follow-up study by Hwang et al. was found to contain errors and the work was
subsequently retracted [126-128].
Straticyte uses image analysis to quantify the expression of S100A7 and
proprietary algorithms based on a clinical reference database of 150 cases, to predict the
progression of pre-malignant to malignant disease [25, 125, 129]. Individualized risk
assessments are then generated that provide a risk prediction for progression to cancer over
5-years.
Although Straticyte has previously shown value in predicting the progression of
oral dysplasia to malignancy [25], to our knowledge it has never been evaluated in
predicting progression of oral dysplasia alone.
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Chapter 2
2.1 Hypothesis
S100A7 levels will be greater in oral epithelial dysplastic lesions that undergo
progression compared to lesions that do not undergo progression.

2.2 Rationale
In addition to the difficulty of clinically detecting a precancerous/cancerous lesion,
there is also often disagreement between pathologists regarding the histologic diagnosis
once the biopsy has been obtained [65, 66]. As the diagnosis of oral cancer is a subjective
process, the search for an objective and quantifiable measure continues to be an important
focus for pre-cancer detection and treatment.
The high morbidity and mortality of oral carcinomas along with the low
transformation rate of PPOELs create a strong demand for reliable early detection [25].
Early detection through biomarkers should lead to more effective disease management.
Biomarkers have the potential to assist with diagnosing OSCC at earlier stages or
identifying pre-malignant conditions before they have transformed to cancer.
Incorporation of reliable biomarkers into the diagnosis of pre-malignant and malignant
lesions will add accuracy and objectivity to the process.
The relatively recent utilization of protein biomarkers for their role in predicting
transformation of pre-malignant oral lesions has produced some favorable results. One of
these biomarkers, S100A7 may be paramount in providing researchers and clinicians with
the utility to objectively evaluate pre-malignant lesions for risk of progression and
ultimately transformation.
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2.3 Aims
1) To show that there is a greater expression of S100A7 in potentially malignant
lesions than in normal epithelial control tissues.
2) To show that there is a greater expression of S100A7 in potentially malignant
lesions that progress to a higher-grade of dysplasia than in lesions that do not
progress.
3) To test whether an image-based algorithm utilizing S100A7, Straticyte, in
potentially malignant lesions accurately predicts progression.
4) To evaluate the expression of -catenin and cyclin D1 in potentially malignant oral
lesions.
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Chapter 3
3.0 Materials and Methods
3.1 Case Selection
Studies were initiated after receiving approval from the Office of Human Research
Ethics at Western University (REB #105954). Cases of potentially malignant oral epithelial
lesions from 2002 – 2017 were retrieved using the Oral Pathology, Schulich School of
Medicine & Dentistry, Western University database. Cases were selected by searching
specimen identification numbers from lists of cases arranged according to their
pathological diagnosis (ie. mild, moderate, severe dysplasia or CIS). Inclusion criteria
required subjects to undergo multiple biopsies (ie. at least 2 biopsies), from the same
anatomic site over a period of time. Specimen paraffin tissue blocks were then retrieved
from the storage archives of the Division of Oral Pathology at Western University. Hospital
cases that were not available from the Western University site, were acquired from London
Health Sciences Centre, University Hospital.
3.1.1 Progressing, Non-progressing & Control Cases
Subjects were then organized into progressing and non-progressing cases. A
progression was defined as any subject who had a subsequent biopsy that was diagnosed
with a higher degree of dysplasia than the previous biopsy. A non-progression was defined
as any subsequent biopsy that either had a lower or equal grade of dysplasia than the
previous one.
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Twenty-five cases were selected to be used as controls. These cases consisted of
hyperkeratosis. The control cases were a single biopsy from an individual at one point in
time. Each case was verified by histological diagnosis by an experienced oral
histopathologist, and categorized as “progressing”, “non-progressing” and “control”. The
distribution of the included cases and the number of biopsies in each category in this study
is presented in Table 3.1.
Table 3.1. Distribution of cases included in the study
Progression

Non-progression

Controls

Cases

29

17

25

Biopsies

66

36

25

The total number of cases and biopsies included in the study was 71 and 127,
respectively. Each case was comprised of at least two biopsies and as many as five biopsies
over a non-specified time interval.
The 29 progressing cases came from 27 subjects. Three subjects had multiple
progressions from the same location over a period of time. For the progressing group, cases
#4 & 5 were from the same subject, cases #7 & 8 were from the same subject and cases
#22 & 23 were from the same subject.
The 17 non-progressing cases came from 17 different subjects. Case #10 of the nonprogressing group had an initial biopsy that was ‘mild dysplasia’ and a subsequent biopsy
that was ‘mild dysplasia with focal moderate dysplasia’, but was re-evaluated by an
experienced oral histopathologist and deemed not to contain moderate dysplasia in the
subsequent biopsy.
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One subject was included in both the progressing and non-progressing groups as
this subject had separate lesions from different locations in the oral cavity, one of which
progressed (case #11 of progressing group) and the other that did not (case #2 of nonprogressing group).
Case #9 (progressing group) had four biopsies from the same site at different
points in time, that when compared to the initial biopsy, each represented a progression.

3.1.2 Specimen Location within the Oral Cavity
No region within the oral cavity was excluded from the study. Anatomic locations
that were deemed to be similar were clustered into a categorical grouping. This categorical
grouping was based on both proximity within the oral cavity and on how the location would
most often be described on the pathology report from the referring surgeon. The various
anatomic locations and their categorical grouping are shown in Table 3.2.
Table 3.2. Location of biopsy and corresponding category
Location

Location Category

FOM

1

Ventral
Tongue/FOM

1

Ventral Tongue

1

Soft Palate

2

Ventrolateral
Tongue

3

Lateral Tongue

3

Gingiva

4

38
Retromolar Pad

5

Buccal Mucosa

6

Lower Lip

7

Dorsal Tongue

8

3.1.3 Demographic Data
From the pathology reports, demographic data such as sex and age at time of biopsy,
was obtained. These reports also provided the date of biopsy, location of biopsy and the
diagnosis. The demographic data for the initial biopsy of the progressing, non-progressing
and control cases included in the study is shown in the Tables 3.3, 3.4 & 3.5.
Table 3.3. Demographic data for progressing cases of oral epithelial dysplasia
Case

Diagnosis

Location

Sex

Age

1

moderate to severe dysplasia

ventral tongue

F

53

2

Mild atypia with hyperkeratosis

FOM

F

39

3

Mild to moderate dysplasia

FOM

M

60

4

moderate to severe dysplasia

FOM

M

70

5

moderate to severe dysplasia with focal CIS

FOM

M

66

6

mild to moderate dysplasia

lateral tongue

M

69

7

Verrucous hyperplasia with early verrucous carcinoma

FOM

F

46

8

mild dysplasia

ventral tongue/FOM

F

49

9

moderate dysplasia

lateral tongue

M

61

10

hyper-orthokeratosis with mild dysplasia

lateral tongue

M

73

11

mild dysplasia

right lateral tongue

M

68

12

moderate dysplasia

ventral tongue

M

49

13

mild dysplasia

FOM

F

53

39
14

amalgam tattoo

FOM

F

78

15

mild to moderate dysplasia

lateral tongue

F

71

16

Mild to moderate dysplasia

lateral tongue

M

47

17

verrucous hyperplasia with moderate epithelial dysplasia

lateral tongue

M

88

18

moderate dysplasia

ventral tongue

M

35

19

mild dysplasia

buccal mucosa

M

73

20

mild dysplasia

lateral tongue

M

65

21

mild dysplasia

ventrolateral tongue

M

59

22

severe dysplasia

lateral tongue

F

75

23

mild to moderate dysplasia

lateral tongue

F

78

24

moderate dysplasia

FOM

M

62

25

mild dysplasia

ventral tongue

F

30

26

mild dysplasia

FOM

F

35

27

mild dysplasia

lateral tongue

M

55

27

mild dysplasia

lateral tongue

M

55

28

mucositis with hyperorthokeratosis

lateral tongue

M

69

29

severe dysplasia

lateral tongue

F

41

40
Table 3.4. Demographic data for non-progressing cases of oral epithelial dysplasia
Case

Diagnosis

Location

Sex

Age

1

moderate to severe dysplasia

soft palate

F

74

2

mild dysplasia

left lateral tongue

M

64

3

CIS

lateral tongue

M

68

4

moderate dysplasia

soft palate

F

60

5

moderate to severe dysplasia

lateral tongue

M

66

6

hyperparakeratosis with chronic mucositis

lateral tongue

F

31

7

moderate to severe dysplasia

lateral tongue

M

37

8

moderate dysplasia

ventrolateral tongue

F

51

9

moderate dysplasia

retromolar pad

F

66

10

mild dysplasia

lateral tongue

M

57

11

mild dysplasia

FOM

M

58

12

mild dysplasia

soft palate

M

71

13

mild dysplasia

lateral tongue

M

66

14

hyperkeratosis with mild epithelial atypia and chronic mucositis

lateral tongue

F

40

14

hyperkeratosis with mild epithelial atypia

lateral tongue

F

40

15

mild dysplasia

FOM

M

60

16

mild dysplasia

lateral tongue

F

65

17

mild dysplasia

ventral tongue

M

63

Table 3.5. Demographic data for controls/normal/hyperkeratosis cases
Case

Diagnosis

Location

Sex

Age

1

Hyperkeratosis with mild epithelial dysplasia

soft palate

F

48

2

hyperkeratosis

lateral tongue

F

61

3

Hyperorthokeratosis

gingiva

M

35

4

hyperkeratosis

retromolar pad

M

59

41
5

Hyperkeratosis

lateral tongue

M

53

6

hyperkeratosis

gingiva

F

43

7

hyperkeratosis

gingiva

F

51

8

hyperkeratosis

FOM

M

30

9

hyperkeratosis

retromolar pad

M

41

10

hyperkeratosis

gingiva

M

48

11

hyperkeratosis

lateral tongue

F

66

12

hyperorthokeratosis

retromolar pad

M

60

13

Hyperparakeratosis

ventral tongue

M

50

14

Hyperkeratosis epithelial architectural atypia

FOM

F

67

15

Hyperparakeratosis

ventral tongue

F

15

16

hyperkeratosis

lateral tongue

F

46

17

hyperkeratosis

lateral tongue

M

36

18

hyperkeratosis

lateral tongue

F

72

19

hyperkeratosis

lateral tongue

F

68

20

hyperkeratosis

dorsal tongue

M

40

21

hyperparakeratosis

lateral tongue

M

24

22

hyperkeratosis

ventral tongue

F

53

23

hyperparakeratosis

lateral tongue

M

66

24

hyperkeratosis

lateral tongue

M

68

25

hyperkeratosis

lateral tongue

F

60

3.1.3.1 Additional Demographic & Risk Factor Data
Because the data provided from the pathology reports was limited, an attempt to
gain additional demographic and risk factor data took place. Using a secured hospital
account, a letter was sent to all referring surgeons requesting the following information:
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•

Was there a history of tobacco use?

•

Was there a history of alcohol use (> 3 drinks/day)?

•

Was the lesion localized or diffuse at the time of biopsy?

•

Is the patient alive or deceased at present?

•

Is the patient still undergoing surveillance?

•

Is the lesion still present?

•

When was the patient last seen?

3.1.4 Diagnosis Category and H&E Evaluation
Once all the subjects/biopsies were selected for the study, the Hematoxylin and
Eosin (H&E) histopathological slides were retrieved and analyzed under the light
microscope with an experienced oral histopathologist and the graduate student author to
ensure agreement with the reported diagnosis. Biopsies consisting of an area deemed to be
‘focal’ were carefully evaluated to ensure that they were placed into the most representative
diagnosis category for the study.
The diagnosis categories included in the study can be seen in Table 3.6.
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Table 3.6. Histopathological diagnosis and corresponding diagnosis category
Diagnosis

Diagnosis Category

Other*

1

Mild Dysplasia**

2

Mild to Moderate Dysplasia

3

Moderate Dysplasia

4

Moderate to Severe Dysplasia

5

Severe Dysplasia

6

CIS

7

Focal Microinvasive SCC

8

* Hyperorthokeratosis, fibrous hyperplasia, mucositis with architectural atypia, ulcerative
granuloma with stromal eosinophilia, amalgam tattoo
** A single case of verrucous carcinoma which is considered to be a low-grade lesion was
placed into this category

3.2 Binary Scoring
An experienced histopathologist and the graduate student author evaluated the H&E
sections for the progressing and non-progressing cases used in the study and reclassified
them according to the 2017 WHO binary ‘high/low’ risk binary scoring system. To be
classified as a ‘high-risk’ lesion, at least 4 architectural and 4 cytological criteria were
required. Criteria can be seen in Table 1.1 in Chapter 1. The experienced oral
histopathologist and the graduate student author evaluated the lesions independently and
were blinded to both the histological diagnosis and the score designated by the other person.
Inter-rater reproducibility, evaluating consistency in scoring between the oral pathologist
and the graduate student author was also measured.
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3.3 S100A7 Staining and Analysis
3.3.1 Specimen Preparation
Paraffin tissue blocks were prepared using a microtome to ensure tissue slices were
representing the full specimen. The blocks were then placed on ice bath for 20 minutes to
ensure tissue hydration. Numerous tissue slices for each of the specimen were created and
placed into a water bath (45C), before they were placed onto charged slides and set into a
warm oven until specimen were used for immunohistochemistry (IHC).
3.3.2 Establishing Optimal Staining Conditions
Prior to performing IHC on the study specimen, optimal experimental conditions
needed to be established. To do this, trial runs were performed to compare pressure cooker
settings at 125C and 112.5C for antigen retrieval. In addition, buffer that contained Tris
(Sigma

Aldrich,

St.

Louis,

MO,

USA)

+

EDTA

(Sigma Aldrich, St. Louis, MO, USA) + Tween 20 (Sigma Aldrich, St. Louis, MO, USA)
and Tris + EDTA without Tween 20 were compared for heat-induced antigen retrieval.
These trial runs determined that tissue was preserved best with Tris + EDTA + Tween 20
and pressure cooker settings at 112.5C; these were the conditions that were used for all
experiments.
3.3.3 Immunohistochemistry (IHC) Protocol for S100A7
Rehydration was performed in the following manner: 100% xylene x 3 (5:5:3
minutes); 100% ethanol x 2 (2:1 minutes); 95% ethanol x 2 (2:1 minutes); 70% ethanol for
2 minutes and then distilled water (dH2O) for 2 minutes. Once brought to water, the slides
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were placed in pressure cooker set to 112.50C with Tris – EDTA buffer pH 9.0 with 0.05%
tween 20.
Staining was performed in the following manner: slides were cooled down in
running tap water and washed three times for three minutes each in TBS-T with gentle
agitation. Next, blocking buffer was applied for 15 minutes using MACH 4 Background
Punisher (Inter Medico, Markham, ON, Canada, Catalogue number: BC-BP974L) (125 l
per slide). Blocking buffer was then drained from the slides and S100A7/Psoriasin mouse
monoclonal IgG1 Kappa (Novus Biologicals Canada, Oakville, ON, Canada, Catalogue
number: NB 100-56559; clone: 47C1068), diluted to 1:2000 in 1.5% horse serum (VWR
International, Toronto, ON, Canada, Catalogue number: 10015-630) in TBS was then
added. Negative controls received 1.5% horse serum alone. Slides were incubated at room
temperature for 1 hour and then rinsed three times, for three minutes in TBS-T with gentle
agitation. Upon completion of incubation, the slides were placed in 3% H2O2 in TBS for
10 minutes to block peroxidase activity, and then washed for 3 minutes once with TBS-T.
Next, 125 l of MACH 4 Mouse Probe (Inter Medico, Markham, ON, Canada, Catalogue
number: BC-M4U534L) was then applied and the specimen were incubated for 15 minutes.
Slides were then washed three times for 3 minutes each in TBS-T. Then 125 l of MACH
4 HRP Polymer (Inter Medico, Markham, ON, Canada, Catalogue number: BC-M4U534L)
was added to the slides and incubated for 15 minutes. Slides were then rinsed three times
for 5 minutes each with TBS-T.
The slides were then developed in DAB (MJS BioLynx Inc., Brockville, ON, Canada,
Catalogue number: VECTSK4100), and care was taken not to keep the solution on for more
than 5 minutes, as the colour change would happen within a minute. The DAB solution
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was always made fresh and used immediately. The DAB solution was made in the
following manner: 5 ml of dH2O, 2 drops (~84 l) of buffer, 4 drops (~100 l) of DAB
and 2 drops (~80 l) H2O2 and mixed well prior to use.
Next, the slides were placed in dH2O. Slides were then counterstained with
haematoxylin (Leica Biosystems Inc., Concord, ON, Canada) for 1 minute and then place
under tap water. Slides were then placed in 1% acid alcohol (HCl/70% Ethanol) and then
washed in running tap water.

Slides were then stained blue in 2% ammonium

hydroxide/70% ethanol and washed in water.
Slides were then dehydrated in the following manner: 70% ethanol (1 minute); 95%
ethanol x2 (1:1 minute); 100% ethanol x3 (1:1:1 minute); xylene x 2 (5:5 minutes) and then
cleared and coverslips were placed using Cytoseal mounting medium (ThermoScientific,
Runcorn Cheshire, WA, USA).
3.3.4 Staining Controls
A known high- and low-risk Straticyte control were included with each staining
experiment. These controls were provided from Proteocyte AI Inc. (Toronto, Ontario,
Canada).
For an understanding on how Straticyte stratified lesions into risk groups see the
section ‘Straticyte Risk Group Determination’ below.
The histopathological images of the positive and negative, high and low-risk
controls can be seen in Figure 3.1.
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Figure 3.1. High- and low-risk S100A7 staining controls. High-risk controls (A (positive
control) & B (negative control)) and low-risk controls (C (positive control) & D (negative
control)). For both high and low-risk positive controls, staining was confined to the middle
and upper layers of the epithelium.
A

C

B

D

3.3.5 Specimen Analysis: Semi-Quantitative and Qualitative
Following IHC, the specimens were analyzed under a light microscope using both
semi-quantitative and qualitative measures. Cells staining positive for S100A7 were
grossly counted throughout the epithelium of the entire specimen.
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Table 3.7. Manual scoring based on the percentage of cells stained
Score

Cells Stained

0

zero

1

1 - 20%

2

21 - 40%

3

41 - 60%

4

61 - 80%

5

81 - 100%

Table 3.8. Manual scoring based on the intensity of staining
Score

Staining Intensity

0

none

1

mild

2

moderate

3

intense

An intensity score was given to whichever intensity was most prevalent within the
entire tissue specimen. These scores were combined to allow for a total score ranging from
0 – 8, with 0 being the lowest score and 8 being the maximum score possible. Tissue level
(ie. basal, parabasal, spinous or surface) of staining was also recorded and whether the
staining was homogenous or focal was noted. Prior to initiating the evaluation, an oral
histopathologist and the graduate student author scored 25 specimens together, to ensure
consistency of methodology, and to avoid inter-and intra-observer bias. On two additional
occasions, for quality assurance, the oral histopathologist and the graduate student author,
rescored an additional 15 specimens each time to ensure consistent and accurate scoring.
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Finally, upon completion of scoring all cases, 20 cases were chosen at random and scoring
was evaluated by the oral histopathologist to ensure scoring calibration was maintained.
Differences in score were < 1 for percentage of cell staining and < 1 for intensity of staining
in all cases. Any discrepancy in scoring was then discussed between the oral
histopathologist and the graduate student author and the agreed upon score was entered. A
scoring difference of < 1 was deemed to be within an acceptable range to ensure cases were
scored accurately using the semi-quantitative and qualitative method.

3.3.6 Specimen Analysis: Quantitative Straticyte Assessment
3.3.6.1 Image and Risk Analysis
The S100A7-stained slides were digitally scanned at 20x magnification on a
Hamamatsu Nanozoomer-XR slide scanner (Toronto Centre for Phenogenomics, Toronto,
Canada). The digital images of the slides were imported into Visiopharm VIS (Hoersholm,
Denmark). Using Visiopharm VIS, up to five 500 µm diameter region of interests (ROIs)
were centered on areas with the highest S100A7 expression in the stratified mucosal
epithelium and the S100A7 positivity (given as a percentage) and average cell size (total
area of the ROIs / total number of identified nuclei) were calculated and used to generate
the Straticyte-risk class and probability of cancer progression. The risk class and
probability of cancer progression algorithm was generated using a clinical reference
database of 150 unique cases (Proteocyte AI Inc., Toronto, Ontario).
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3.3.6.2 Straticyte Risk Group Determination and Probability of 5-year Cancer
Progression
Selection cut-off was determined based on the two following rules:
1. For all cases, a high cut-off was selected to differentiate the high-risk and non-highrisk groups, with specificity >85% and P value of log rank test between high- and
non-high-risk groups <0.05.
2. For cases in the non-high-risk group, a low cut-off was selected to differentiate
medium-risk and low-risk groups with sensitivity >90% and P value of log rank
test between the medium- and low-risk groups <0.05.
For both cut-offs, once the criteria were met, the cut-off that gave the best-balanced
accuracy (average of sensitivity and specificity) was chosen [25, 129].
The Nelson-Aalen-Breslow estimate, used to calculate the baseline cancer-free
survival curve, was combined with the calculated risk scores from the 150 unique cases, to
produce the expected 5-year cancer-free survival probability for a given case. Once this 5year cancer progression algorithm is calculated, a new case can be assessed a 5-year
probability of cancer progression and assigned a low-, medium-, or high-risk [25, 129].
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Table 3.9. Straticyte risk group and associated probability of cancer progression
over 5 years
Probability of Cancer progression

Risk Group

 60%

High

19%  and  60%

Medium

 19%

Low

Adapted from [25, 129]

Figure 3.2. Straticyte Analysis Image. Regions of interest (ROIs) are outlined in
dashed blue and two overlapping ROIs can be seen. Within the ROIs: red = S100A7negative cytoplasm; green = S100A7-negative nuclei; maroon = S100A7-positive
cytoplasm and blue = S100A7-positive nuclei. Image provided by Dr. J. Hwang,
Proteocyte AI, Toronto, ON, Canada.

Only segmented pixels from inside of the ROIs are used for final calculation of S100A7
positivity and average cell size [25, 129].
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3.3.6.3 Total Epithelium Assessment
For total epithelium assessment, the entire epithelium from the surface to the basement
membrane was manually annotated as the ROIs and the S100A7-positive area, S100A7negative area, and the total area of the ROIs were analyzed and used to calculate the
percentages of S100A7-positive and -negative areas. Lesions diagnosed as carcinoma were
omitted from the total epithelium assessment as in many instances, the epithelium was
difficult to clearly identify for manual annotation of ROIs.
Figure 3.3. Measure of total area of S100A7 staining within entire epithelium. The
ROI are outlined in dashed green and within the ROI: blue = S100A7-negative pixels and
green = S100A7-positive pixels. Image provided by Dr. J. Hwang, Proteocyte AI,
Toronto, ON, Canada.

[25, 129].
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3.4 -catenin Staining and Evaluation
3.4.1 Specimen Preparation and -catenin Staining
Monoclonal mouse anti-human -catenin (code No. IR702) was obtained from
DAKO (Glostrup, Denmark). Automated staining at University Hospital, London, ON,
Canada, was performed according to the manufacturer’s instructions.
Tissue specimens were cut into sections of approximately 4 m. Pre-treatment with
heat-induced epitope retrieval (HIER) was performed using Dako PT Link. The tissues
were pretreated using EnVision FLEX Target Retrieval Solution, High pH (50x) (Code
K8004).
Pre-treatment of formalin-fixed, paraffin-embedded tissue sections was performed
using the 3-in-1 specimen preparation procedure for Dako PT Link. Following staining,
the sections were dehydrated, cleared and mounted.
The staining steps and incubation times were pre-programmed into the Autostainer
Link software. The visualization system was EnVision FLEX, High pH (Link) (Code
K8000). Reagents were applied in a volume 1 x 200 L per slide. All incubation steps were
performed at room temperature. Counterstaining was performed in hematoxylin using
EnVision FLEX Hematoxylin (Link) (Code K8008). Positive and negative control tissues
as well as negative control reagent were run simultaneously using the same protocol as the
case specimens. The negative control reagent was FLEX Negative Control, Mouse (Link)
(Code IR750).
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3.4.2 -catenin Evaluation
A qualitative assessment was used to evaluate the staining of -catenin.
3.4.3 -catenin Control
Figure 3.4. -catenin control from gastrointestinal tissue (GIT). Original magnification
x200. Positive staining (brown) is seen within the cytoplasm and cytoplasmic membrane
of the epithelial tissue.

3.5 Cyclin D1 Staining and Evaluation
3.5.1 Specimen Preparation and Cyclin D1 Staining
Monoclonal rabbit anti-human Cyclin D1 (code No. IR083) was obtained from the
manufacturer, DAKO. Automated staining was performed at University Hospital, London,
ON, Canada.
Tissue specimens were cut into sections of approximately 4 m. Pre-treatment with
heat-induced epitope retrieval (HIER) was performed using Dako PT Link. Tissues were
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pretreated using EnVision FLEX Target Retrieval Solution, High pH (50x) (Code K8004)
for 20 minutes at 97°C followed by 5 minutes in EnVision FLEX Wash Buffer (20x) (Code
K8007).
The visualization system was EnVision FLEX, High pH (Link) (Code K8000). The
staining steps and incubation times were pre-programmed into the Autostainer Link
software. The reagent application volume was 1 x 200 L per slide. All incubation steps
were performed at room temperature.
Counterstaining in hematoxylin was done using EnVision FLEX Hematoxylin
(Link) (Code K8008). After staining, the sections were dehydrated, cleared and mounted.
Positive and negative control tissues as well as negative control reagent were run
simultaneously using the same protocol as the case specimens. The negative control reagent
was FLEX Negative Control, Rabbit (Link) (Code IR600).
3.5.2 Cyclin D1 Evaluation
A qualitative assessment was used to evaluate the staining of cyclin D1.

56
3.5.3 Cyclin D1 Control
Figure 3.5. Cyclin D1 control from lymphoid tissue. Original magnification x200.
Positive staining (brown) is seen within the nucleus.

3.6 Statistical Analysis
Statistical Analysis was performed using Instat GraphPad Prism 8 (GraphPad
Software, San Diego, CA, USA). The level of significance was set at P < 0.05.
To compare progressing, non-progressing and control cases for manual and
automated (Straticyte) scoring methods, both a Kruskal-Wallis test and a BrownForsythe ANOVA test were utilized. A Mann-Whitney test and a Welch’s T test were
performed to compare both progressing to non-progressing cases and progressing to control
cases.
To identify which scoring method had the best ability to predict disease progression,
a binary logistic regression model was used to compare non-progressing to control cases
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and non-progressing to progressing cases. A Pearson Correlation Coefficient was used to
asses for correlation between variables for the entire data set. A Pearson Correlation
Coefficient was also used to identify variable correlation when comparing control to nonprogressing cases and non-progressing to progressing cases.
Step-wise regression utilizing a method called ‘forward-backward selection’ to find
the most parsimonious model without losing predictive power was then used to identify
the variables most predictive of control vs. non-progressing outcomes and non-progressing
vs. progressing outcomes. This was presented as odds ratio with 95% confidence intervals.
Variance inflation factors were evaluated to assess for multicollinearity, a measure
to ensure that the input variables are not unduly influencing one another, making it difficult
to evaluate the dependent variable or outcome [130].
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Chapter 4
4.0 Results
4.1 Anatomic Location
In Tables 4.1, 4.2 and 4.3 are the distribution of the anatomic locations for the
progressive, non-progressive and control/hyperkeratosis cases:
Table 4.1. Location category of initial biopsy for progressing cases
Location

Cases

FOM/Ventral
Tongue

14

Soft Palate

0

Lateral Tongue

15*

Gingiva

0

Retromolar Pad

0

Buccal Mucosa

1

Lower Lip

0

Dorsal Tongue

0

*Initial biopsy of Case #27 had two specimens

Table 4.2. Location category of initial biopsy for non-progressing cases
Location

Cases

FOM/Ventral
Tongue

3

Soft Palate

3

Lateral Tongue

11*
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Gingiva

0

Retromolar Pad

1

Buccal Mucosa

0

Lower Lip

0

Dorsal Tongue

0

*Initial biopsy of Case #14 had two specimens

Table 4.3. Location category of initial biopsy for control/hyperkeratosis/normal
cases
Location

Cases

FOM/Ventral
Tongue

5

Soft Palate

1

Lateral Tongue

11

Gingiva

4

Retromolar Pad

3

Buccal Mucosa

0

Lower Lip

0

Dorsal Tongue

1

For progressing cases, most of the biopsies came from the lateral tongue and ventral
tongue/FOM. For non-progressing and control cases, the lateral tongue was the most
common anatomical site.
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4.2 Diagnosis
Table 4.4. Diagnosis category of initial biopsy for progressing cases
Diagnosis

Cases

Other/Normal

3 (10%)

Mild Dysplasia*, **

12 (40%)

Moderate Dysplasia

10 (33%)

Severe Dysplasia

5 (17%)

*Included one case of verrucous hyperplasia with early verrucous carcinoma as
this is considered a low-grade lesion
**Initial biopsy of Case #27 had two specimens

Table 4.5. Diagnosis category of initial biopsy for non-progressing cases
Diagnosis

Cases

Other/Normal *

3 (17%)

Mild Dysplasia

8 (44%)

Moderate Dysplasia

3 (17%)

Severe Dysplasia

4 (22%)

*Initial biopsy of Case #14 had two specimens

Table 4.6. Diagnosis category for initial biopsy of control/hyperkeratosis/normal
cases
Diagnosis

Cases

Other/Normal

25 (100%)

Mild Dysplasia

0 (0%)

Moderate Dysplasia

0 (0%)

Severe Dysplasia

0 (0%)
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The most common diagnosis for progressing and non-progressing cases was mild
dysplasia. The controls were all normal tissue/hyperkeratosis.
4.3 Age of Subjects

Figure 4.1. Median age at the time of initial biopsy. Statistical comparison using
Kruskal-Wallis test (p = 0.10). *p < 0.05; **p < 0.01
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Although not statistically significant (p = 0.10), progressing cases had a higher
age at time of initial biopsy relative to non-progressing and control cases. Median age for
the progressing, non-progressing and control groups was 59.1 years, 57.6 years and 50.4
years respectively.
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4.4 Sex of Subjects
Figure 4.2. Sex of subjects for progressing cases

Number of Cases

20
15
10
5
0

Male

Female

Figure 4.3. Sex of subjects for non-progressing cases

Number of Cases

10
8
6
4
2
0

Male

Female
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Figure 4.4. Sex of subjects for controls/hyperkeratosis/normal

Number of Cases

15

10

5

0

Male

Female

The predominant sex for progressing cases was male. Sex was more evenly
distributed for the non-progressing and control groups.

4.5 Additional Demographic & Risk Factor Data
From the census sent out to the referring surgeons, the response rate was 18/27 =
67% and did not allow for any useful statistics to be obtained. The reasons for surgeon’s
lack of participation in the study included: unwilling (1), deceased (1), retired (3),
unknown/did not reply (4). In addition to this, all the initial pathology reports were
evaluated to determine if the biopsies were incisional or excisional and due to the small
number of reports that provided this information, it was determined not to include this
information in the study. The results from this census are provided in Table 4.7.
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Table 4.7. Additional demographics & risk factor data from referring surgeon

Subject #

Sex

Location

Alcohol

Tobacco

Localized/
Diffuse

1

M

FOM

Yes

Yes

Localized

2

F

Soft palate

3

F

FOM

No

No

Diffuse

4

F

FOM

No

5

M

Lateral
tongue

No

6

F

Ventral
tongue

7

M

Lateral
tongue

8

M

9

Alive

Yes

Still following/last
evaluated

Still persisting

October 2013

No

Yes

Diffuse

March 2013

No

Diffuse

2010

No

No

Localized

Yes

Lateral
tongue

Yes

Yes

Diffuse

No (Lung
Cancer)

F

Lateral
tongue

No

No

Localized

Yes

Yes

10

M

FOM

11

M

FOM

12

M

Lateral
tongue

No

No

Localized

Yes

October 2007

13

F

Soft Palate

No

No

Localized

Yes

Yes

14

F

Lateral
tongue

No

No

Localized

Yes

Yes

15

M

Lateral
tongue

16

M

Lateral
tongue

17

F

Retromolar
pad

18

F

Ventral
tongue

No

Yes

Localized

Yes

Yes

19

M

Lateral
tongue

No

No

Localized

Yes

September 2012

20

M

Lateral
tongue

21

M

Lateral
tongue

Yes

Yes

Localized

Yes

April 2015

22

M

Lateral
tongue

Yes

Localized

Yes

September 2011

No

No
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23

M

Buccal
mucosa

24

M

Lower lip

No

No

Diffuse

Yes

Yes

25

F

Lateral
tongue

No

No

Localized

Yes

February 2017

SCC in 2015; nothing since

26

F

Lateral
tongue

Yes

Yes

Localized

Yes

2015

No

27

F

Lateral
tongue

No

No

Localized

No (MI)

4.6 Straticyte risk group for progressing, non-progressing & control cases
Table 4.8. Straticyte risk group for initial biopsy of progressing cases
Straticyte Risk
Group

Cases

Low

9 (30%)

Medium

20* (67%)

High

1 (3%)

*Case 27 had two initial biopsy specimens

Table 4.9. Straticyte risk group for initial biopsy of non-progressing cases
Straticyte
Risk Group
Low

Cases

Medium

4 (22%)
12*
(67%)

High

2 (11%)

*Case 14 had two initial biopsy specimens
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Table 4.10. Straticyte risk group for initial biopsy of
controls/normal/hyperkeratosis cases
Straticyte
Risk Group

Cases

Low

6 (24%)

Medium

18 (72%)

High

1 (4%)

Medium risk was the most common risk group amongst progressing, non-progressing and
control groups.
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4.7 Immunohistochemistry (IHC)
4.7.1 S100A7
Figure 4.5. Illustrative S100A7 cytoplasmic and nuclear staining (brown). Case #2 of
progressing group. Diagnosis = mild to moderate dysplasia; manual score = 4 (cell
score = 2; intensity score = 2); Straticyte score = 32.03). A = original magnification
x50; B = original magnification x100; C = original magnification x200

A)

B)

C)
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Figure 4.6. Illustrative S100A7 staining for initial biopsy of Case #28: Diagnosis =
mucositis with hyperorthokeratosis; manual score = 6 (cell score = 4; intensity score
= 2); Straticyte score = 26.48). Staining confined to upper layers of epithelium
with sparing of the basal and parabasal layers. A = original magnification x50; B =
original magnification x100; C = original magnification x200

B)

A)

C)
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Figure 4.7. Illustrative S100A7 staining for subsequent biopsy of Case #28:
Diagnosis = moderate to severe dysplasia; manual score = 6 (cell score = 3; intensity
score = 3); Straticyte score =18.02). Staining present in both the cytoplasm and
nucleus. A = original magnification x100; B = original magnification x200

A)

B)

4.7.1.1 Qualitative Evaluation of S100A7 Staining
S100A7 immunoreactivity was present in both the cytoplasm and the nucleus
although more prominent in the cytoplasm. Staining was limited to the middle and
superficial layers of the epithelium. Staining was not evident in the basal layer. Intensity
of staining was variable.
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4.7.2 Cyclin D1

Figure 4.8. Illustrative Cyclin D1 staining. Case #15 of lateral tongue. Diagnosis =
moderate dysplasia. Staining confined to nucleus of basal and parabasal layer. A =
original magnification x50; B = original magnification x200.

B)

A)

4.7.2.1 Qualitative Evaluation of cyclin D1 Staining
Cyclin D1 staining was isolated to the basal and parabasal layers and was most
prominent in the parabasal layer. Staining occurred in both the nuclei and the cytoplasm,
with nuclei staining being most prominent. There was no identifiable difference on cyclin
D1 staining with any of the various grades of dysplasia and quantitative evaluation was
not performed.
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4.7.3 -catenin

Figure 4.9. Illustrative -catenin staining. Case #15 of lateral tongue. Diagnosis =
moderate dysplasia. Staining occurring in the cytoplasm and cytoplasmic membrane
in basal and parabasal layers and cytoplasmic membrane in layers higher up in the
epithelium. A = original magnification x50; B = original magnification x200.

A)

B)

4.7.3.1 Qualitative Evaluation of -catenin Staining
-catenin staining was most prominent in the basal and parabasal layer of the
epithelium. At all levels of the epithelium, -catenin stained the outer cell membranes. At
the basal and parabasal levels, -catenin was also present in the cytoplasm, but cytoplasmic
staining was not evident at levels beyond the parabasal layer. No significant staining was
identified in the nucleus. -catenin staining did not show any difference between various
grades of dysplasia and as such, quantitative analysis could not be performed.
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4.8 Statistical Analysis
4.8.1 Initial Biopsy Score Evaluation
4.8.1.1 Manual Scoring Method
Figure 4.10. Total manual score for initial biopsy of progressing, non-progressing
and hyperkeratosis/normal/control cases. Statistical comparison using KruskalWallis Test (p = 0.01) and by Brown-Forsythe ANOVA Test (p = 0.01). *p < 0.05;
**p < 0.01
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Figure 4.11. Total manual score for initial biopsy of progressing and nonprogressing cases. Statistical comparison using Mann-Whitney Test (p = 0.69) and
Welch’s T Test (p = 0.85). *p < 0.05; **p < 0.01
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Figure 4.12. Total manual score for initial biopsy of progressing and control cases.
Statistical comparison using Mann-Whitney Test (p = 0.004) and Welch’s T Test (p
= 0.004). *p < 0.05; **p < 0.01
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Comparing all three groups (progressing, non-progressing and control) and
comparing progressing to control cases using the manual scoring method achieved a
statistically significant result with P = 0.01 and P = 0.004, respectively. However,
comparison of progressing and non-progressing cases using the manual scoring method did
not achieve a statistically significant result.

4.8.1.2 Automated (Straticyte) Scoring Method

Straticyte score - 5 year risk of progression (%)

Figure 4.13. Automated (Straticyte) score for initial biopsy of progressing, nonprogressing and hyperkeratosis/normal/control cases. Statistical comparison using
Kruskal-Wallis Test (p = 0.24) and by Brown-Forsythe ANOVA Test (p = 0.18). *p
< 0.05; **p < 0.01
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Straticyte score - 5 year risk of progression (%)

Figure 4.14. Automated (Straticyte) score for initial biopsy of progressing and
non-progressing cases. Statistical comparison using Mann-Whitney Test (p = 0.10)
and Welch’s T Test (p = 0.09). *p < 0.05; **p < 0.01
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Figure 4.15. Automated (Straticyte) score for initial biopsy of progressing and
control cases. Statistical comparison using Mann-Whitney Test (p = 0.33) and
Welch’s T Test (p = 0.25). *p < 0.05; **p < 0.01
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Comparison of all three groups (progressing, non-progressing and controls) using
Straticyte did not achieve a statistically significant result. Neither did comparison of
progressing to non-progressing cases or progressing to control cases.

4.8.2 Binary Scoring
Tables 4.11 and 4.12 are WHO binary scoring for the initial biopsy of the progressing
and non-progressing cases. Scoring was performed by an experienced oral
histopatholgist.

Table 4.11. WHO binary scoring of initial biopsy for progressing cases shown as
both the number and percentage (%) of cases.
High Grade

Low Grade

19 (73.1%)

7 (26.9%)

Table 4.12. WHO binary scoring of initial biopsy for non-progressing cases shown
as both the number and percentage (%) of cases.
High Grade

Low Grade

7 (46.7%)

8 (53.3%)

Comparing progressing to non-progressing cases using the binary scoring system
resulted in progressing cases having a greater percentage (73.1% vs 46.7%) of high-grade
lesions and non-progressing cases having a greater percentage (53.3% vs 26.9%) of lowgrade lesions.
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Table 4.13. Inter-rater reproducibility using WHO binary score system for the
initial biopsy of progressing cases. Scoring was performed by an experienced oral
histopathologist and the graduate student author.
Same scoring

Different scoring

19 (73.1%)

7 (26.9%)

Table 4.14. Inter-rater reproducibility using WHO binary score system for the
initial biopsy of non-progressing cases. Scoring was performed by an experienced
oral histopathologist and the graduate student author.
Same scoring

Different scoring

14 (93.3%)

1 (6.7%)

Inter-rater reproducibility using the binary scoring system resulted in a high
percentage of same score designation between the experienced oral histopathologist and
the graduate student author for both progressing (73.1%) and non-progressing (93.3%)
cases.
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4.8.3 Correlation Analysis
4.8.3.1 Evaluation of Entire Dataset
Figure 4.16. Pearson’s Correlation Coefficient of Variables used for S100A7
evaluation of all cases in the study. Brown/red squares indicated a positive
association/correlation and blue/purple squares indicate a negative
association/correlation.

There is a strong linear correlation observed between: 1) Straticyte risk group and
automatic scoring; 2) manual scoring and area stained. There was a moderately positive
correlation between the automatic and manual scoring methods.
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Figure 4.17. Distribution of variables for initial biopsy of entire dataset.

Sex was well distributed with a slight tendency towards males. There were almost
two times as many progressing cases as there were non-progressing cases. The most
common diagnosis was mild dysplasia (not including control cases which were primarily
hyperkeratosis). The most common location was the lateral tongue followed by the
FOM/ventral tongue. Most subjects fell between the age of 50 – 75 years old and most
specimen had a Straticyte risk of medium.
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4.8.3.2 Control vs. Non-Progressing Cases
A binary logistic regression model was applied to compare controls to nonprogressing cases using all the same previously described variables as covariates. The
response is whether the individual is healthy (control) or if the individual has a nonprogressing lesion. Table 4.15. is a summary of the modelled output.
Table 4.15. Binary logistics regression of control vs. non-progressing lesions

It appears that the only statistically significant value in this model is the manual
scoring, as it provided a p-value closest to 0.05.
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Figure 4.18. Pearson Correlation Coefficient for controls vs. non-progressing cases.
Brown/red squares indicated a positive association/correlation and blue/purple squares
indicate a negative association/correlation.

There is no strong connection between the automatic and the manual scoring
methods.
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Figure 4.19. Variance inflation factors for controls vs. non-progressing cases
showing there is no strong multicollinearity

Figure 4.19 shows variance inflation factors for the variables. It is a measure of
multicollinearity (ie. how close are different variables to being linear combinations of one
another?). Values below 10 are considered reasonably dissimilar to one another and
considered not to have multicollinearity. Multicollinearity creates a problem because it
suggests input variables are influencing one another making it difficult to test how much
the combination of the independent variables affect the dependent variable or outcome
[130].
We do not see a strong variance inflation from either of the scoring methods,
suggesting no significant multicollinearity is present, thus giving us confidence in our
results and conclusions.

83
Table 4.16 is a step-wise regression method called forward-backward selection and it picks
the most parsimonious model without losing prediction power. The final model ended up
using only the Age and Manual Scoring selection variables.
Table 4.16. Step-wise regression analysis of controls vs. non-progressing cases

Based on this regression model, manual scoring was found to be highly significant.
Age, while not being individually significant, may have an impact on the result when paired
with manual scoring.

Table 4.17. Odds ratio contributions for each variable in the final model along with
95% confidence intervals

The odds ratio is defined as:

Therefore, a 1-point increase in the manual scoring variable equates to an increase
in the odds ratio by 1.88, indicating a higher probability that the patient will have a nonprogressing lesion.
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4.8.3.3 Non-progressing vs. Progressing Cases
Once again, a binary logistic regression model was applied to compare nonprogressing to progressing cases using all the same previously described variables as
covariates. The response is whether the individual has a non-progressing or a progressing
lesion. Table 4.18 is a summary of the modelled output.

Table 4.18. Binary logistic regression for non-progressing vs progressing cases

Only the automatic (Straticyte) scoring method approaches significance (P = 0.092) to
the response in the presence of the other variables.
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Figure 4.20. Pearson correlation coefficient for non-progressing vs. progressing
cases. Brown/red squares indicated a positive association/correlation and blue/purple
squares indicate a negative association/correlation.

Figure 4.20 suggests there is no strong connection between the automatic and
manual scoring methods.
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Figure 4.21. Variance inflation factors for non-progressing vs. progressing cases
showing there is no strong multicollinearity.

Table 4.19 shows the variable selection using a step-wise regression method called
forward-backward selection and it picks the most parsimonious model without losing
prediction power to determine which variables are the best predictors of progressing and
non-progressing cases
Table 4.19. Step-wise regression for non-progressing vs. progressing cases

Automatic scoring had some significance on its own suggesting that it is the best
predictor of progression likelihood, however, there is only weak evidence (t-test p-value is
0.078). The manual scoring method did not have a strong predictive value.
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Table 4.20. Odds ratio and 95% confidence interval for non-progressing vs.
progressing cases

A single point of increase in the automatic scoring variable leads to about a single point
increase in the odds ratio.

In this case, the odds ratio is defined as:
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Chapter 5
5.0 Discussion
5.1 Anatomic Location
For progressing cases, most of the biopsies came from the lateral tongue and ventral
tongue/FOM. The lateral tongue and ventral tongue/FOM are considered high risk sites for
oral cancer [57, 58]. It was interesting that for the progressing group, the lateral tongue and
ventral tongue/FOM were almost the exclusive anatomic sites, further supporting the
notion that these are high risk sites.
For non-progressing and control cases, the lateral tongue was the most common
anatomical site. Although other anatomic sites were also represented, the lateral tongue
and ventral tongue/FOM were still the most common anatomic sites, suggesting that these
tend to be the most common sites for leukoplakia in general.

5.2 Age
Progressing cases had a higher age at time of initial biopsy relative to nonprogressing and control cases. This is consistent with the literature where advanced age has
been shown to be a risk factor for cancer development [58, 62].
5.3 Sex
There was a slight trend towards progressing lesions being identified in males.
There was almost equal sex distribution for non-progressing and control cases. The
literature suggests that oral potentially malignant lesions are more common in males,
however, rates of transformation tend to be higher in females and the reasons for this are
not completely understood [12, 13]. Our study did not specifically evaluate transformation
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to malignancy so we were not able to compare this outcome to what has been seen
previously in the literature in terms of sex predilection.
5.4 Biomarkers
5.4.1 S100A7
Prior work with S100A7 has shown it to be a potentially useful biomarker in
predicting a poor outcome in head and neck carcinoma [107] and as a risk factor for
transformation from oral dysplasia to carcinoma [108]. Hwang et al. have also tested the
predictive value of S100A7 [25].
We hypothesized that S100A7 would have higher levels in potentially malignant
lesions that underwent progression compared to lesions that did not progress. In this study,
S100A7 staining was present in all three groups: progressing, non-progressing and control
(normal tissue). The findings of this study did not show that S100A7 was overexpressed in
progressing lesions compared to non-progressing lesions, but rather, S100A7 expression
was similar between the two groups. S100A7 expression was evaluated using both manual
and automated scoring methods and neither method showed that S100A7 expression was
significantly higher in the progressing lesions compared to non-progressing lesions. This
finding suggests that more work is needed to determine if S100A7 is a useful predictor for
progression of potentially malignant oral lesions and in further understanding the role of
S100A7 in tumour development and progression.
S100A7 is known to have many physiologic functions such as chemotaxis for
inflammatory mediators [82-84], matrix remodelling and angiogenesis [103]. In all cases,
S100A7 expression was mostly limited to the middle and upper layers of the epidermis,
with the basal and parabasal layers being spared. This is common to what has been
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described previously in psoriatic patients [92]. By being expressed only in the upper layers
of the epidermis, S100A7 only begins to be expressed as the epithelial cells mature and
move

closer

towards

the

surface

suggesting

that

S100A7

is

induced

in

differentiated/differentiating cells.
S100A7 has also been speculated to have a protective function against invasion
[100]. Differential expression of S100A7 mRNA has been seen in DCIS compared with
invasive breast cancers; in which S100A7 is overexpressed in DCIS and minimally
expressed in invasive breast cancers [98]. A study evaluating S100A7 expression in
traumatic fibromas and normal tissue has revealed S100A7 to be over 10-fold higher in
traumatic fibromas than that of normal tissue, prompting the authors to suggest a protective
function for S100A7 against invasion, as traumatic fibromas grow in size but rarely
transform to malignancy or invade [131]. A study by Probstmeier et al. that evaluated the
expression of four different S100 proteins in healthy gingiva, traumatic fibromas,
leukoplakia and OSCC, found increased expression of S100A7 in traumatic fibromas,
leukoplakia and OSCC relative to healthy controls, with all being statistically significant
[132], however, this study did not mention if it was evaluating poorly or well differentiated
OSCC.
In keratinocyte cell lines, S100A7 expression has been shown to be higher in CIS
and differentiated SCC, than it is in undifferentiated SCC, further supporting that S100A7
may have a protective role [95]. Another study found S100A7 to be highly expressed in
pre-invasive and early staged, well-differentiated OSCC but minimal or no expression of
S100A7 was found in late staged, undifferentiated and invasive OSCC [94]. A prospective
study evaluating S100A7 expression levels in OSCC would help to further improve our
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understanding of S100A7 and its potential protective role against tumour progression and
invasive malignancy.
Pre-malignant and malignant lesion progression has been shown to be related to
accumulated genetic alteration [20, 21, 33, 34]. Risk factors such as alcohol and tobacco
are some of the main causes of genetic alteration leading to OSCC [34]. It would be useful
to determine the relationship between tobacco and alcohol consumption to the expression
of S100A7. If S100A7 has a protective role for tumour progression, it would be anticipated
that alcohol and tobacco consumption may be associated with decreased expression of
S100A7. Unfortunately, in this study we did not evaluate the correlation of known risk
factors with progressing and non-progressing lesion groups or the expression of S100A7.
The reason for this was an inability to obtain sufficient demographic and risk factor data
from the referring clinicians. A future study looking at the relationship between alcohol
and tobacco consumption and S100A7 expression would be useful in further understanding
the protein biomarkers role.

5.4.2 Cyclin D1
Cyclin D1 is a known cell cycle regulator and has been linked to many oncogenic
functions [116, 119]. In this study, cyclin D1 was expressed primarily in the basal and
parabasal layers of all oral dysplastic lesions. There was no differential staining in the
various grades of dysplasia and cyclin D1 did not appear to be a useful marker in predicting
progression of oral dysplastic lesions.
Another study found cyclin D1 to be expressed in OSCC, however, in oral dysplasia
it was cyclin E, rather than cyclin D1 that was expressed [122]. This could be one
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explanation for not noticing a difference in the pre-malignant phase and perhaps cyclin E
would be a more useful marker for predicting pre-malignant progression.
Another study found similar expression of cyclin D1 in oral epithelial dysplasia and
OSCC [121]. These authors also observed that approximately 10% of normal epithelium
expresses cyclin D1. Other studies have also shown that cyclin D1 nuclear staining in
normal skin tissue will range between 5-40% of cells [133]. Rousseau et al. also observed
that staining in normal tissue is often confined to the basal and parabasal layers but can be
seen higher up in the epithelium in dysplasia. This was not observed in our study as staining
was only observed in basal and parabasal layers in both normal and dysplastic lesions.
To our knowledge, there have been no studies comparing the direct relationship
between S100A7 and cyclin D1. Because there was no observed differential staining for
any of the potentially premalignant oral lesions in this study we did not evaluate the
expression of S100A7 and cyclin D1 simultaneously in each of our samples to determine
if a relationship exists.
As S100A7 has been suggested to have a protective function against tumour
progression and invasiveness [94], and overexpression of cyclin D1 has been associated
with advanced clinical disease and a worse prognosis in both laryngeal [120] and OSCC
[116, 134], evaluating the expression of S100A7 and cyclin D1 at varying stages of OSCC
might be useful to determine if there is a reciprocal relationship, as has been suggesting
between S100A7 and -catenin [94].
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5.4.3 -catenin
-catenin plays a central role in the Wnt cascade. In the absence of Wnt signalling,
-catenin is targeted for proteolytic degradation, however, in the presence of Wnt protein,
-catenin avoids degradation, and its levels increase in the cytoplasm, eventually leading
to its transport to the nucleus where it is involved with transcription of Wnt-regulated genes,
some of which may be involved in cancer development and progression [110, 112, 113].
The -catenin-cadherin complex is important for cell adhesion and fulfills a
protective role against invasion and spread. Loss of the -catenin-cadherin complex is
considered to be a late event in tumourigenesis as its loss has been observed with invasion,
metastasis and loss of differentiation [114].
S100A7 and -catenin are believed to have a reciprocal effect on one another such
that S100A7 can target -catenin for degradation via a non-canonical mechanism and that
downregulation of S100A7, increases -catenin signalling leading to promotion of tumour
growth and progression [94].
In the present study, -catenin expression was present in the cytoplasmic membrane
at all levels of the epithelium. It was also present in the cytoplasm of the basal and parabasal
layers only. In neoplastic processes, -catenin expression is shown diffusely through the
cytoplasm and within the nucleus [135]. As this study only evaluated potentially premalignant oral lesions, -catenin was not expected to stain the nucleus and cytoplasm
diffusely and it did not.
A follow up study that prospectively evaluated -catenin and S100A7 levels in
individuals with differentiated, early OSCC and in individuals with undifferentiated,
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advanced OSCC may further help to explain the relationship between S100A7 and catenin.

5.5 Comparison of Automated (Straticyte) and Manual Scoring Methods
In evaluating the utility of predicting progression of oral epithelial dysplasia,
neither the automated (Straticyte) or the manual scoring methods proved to be superior
to one another. Evaluation of the initial biopsies for progressing, non-progressing and
control cases, showed the manual scoring method to be better at predicting progression
than the automated method, and this result was statistically significant when analyzed using
Brown-Forsythe and Kruskal-Wallis tests (P=0.01). However, when this result was
analyzed more closely, the manual scoring method was useful for differentiating the
progressing and control groups (P=0.004), but not the progressing and non-progressing
groups.
Further evaluation, using the binary logistics regression model with step-wise
regression, although not statistically significant (P=0.08), showed the automated scoring
method was better at predicting progression of oral dysplasia than the manual scoring
method.
Due to the variability in results, it is difficult to conclude that either the manual or
automated (Straticyte) method were superior to the other.
One explanation for this is that Straticyte was designed to predict progression of
dysplasia to malignancy and this study was evaluating the utility of Straticyte in
predicting progression of oral dysplasia alone. It could be possible that the algorithms
Straticyte uses to predict progression to malignancy are not useful or sensitive enough to
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predict progression of dysplasia alone; to our knowledge, this has not been evaluated
previously. As the development of OSCC is believed to proceed in a stepwise fashion
through increasing degrees of oral dysplasia [19], we felt that in being able to predict which
oral dysplastic lesions will progress, this would ultimately assist with cancer prevention
and was one of the rationales for doing this study.
When comparing non-progressing and control cases using binary logistics
regression, the manual scoring method appeared to be superior to the automated method
and this result was statistically significant (P=0.016). This suggests that S100A7
expression as evaluated through the manual scoring method was useful at differentiating
healthy controls from non-progressing oral dysplastic lesions.
Analysis of the entire dataset showed a strong linear correlation between the manual
scoring method and the computer evaluation of ‘the area stained’ with S100A7. The
manual scoring method and ‘the area stained’ having a strong correlation is important
because one of the variables of the manual scoring method was the percentage of cells
stained. The percentage of cells stained was estimated by an experienced oral
histopathologist and the graduate student author for each sample. The computer evaluation
of the epithelial area stained with S100A7 and the manual scoring method were positively
correlated. This suggests that percentage of cells stained as evaluated by the oral
pathologist and the graduate student was similar to the area calculated by the computer.
There was also a moderately positive correlation between the automatic and manual
scoring methods when analyzed using Pearson Correlation Coefficient, suggesting that
both methods were evaluating the same thing.
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5.6 Binary Scoring System
At the moment, there is no biomarker that has proven to be consistently superior to
histopathological diagnosis in predicting progression of oral dysplasia or transformation to
malignancy. Therefore, evaluation of oral dysplastic lesions by two experienced oral
histopathologists, using a binary system for diagnosis, with well-defined criteria, into lowand high-risk lesions, may still be the most objective method. Although the results of a
binary system in predicting transformation to malignancy have been mixed, the inter-rater
reproducibility and agreement has previously been shown to be improved [22, 71, 72].
Evaluation of the utility of the binary scoring system in our study produced inter-rater
reproducibility of 73.1% and 93.3% for progressing and non-progressing cases,
respectively.
Utilizing a binary system may mean that overall, fewer lesions are excised, as the
binary system will divide the moderate dysplasia group into low- and high-risk lesions.
Currently, in most clinical practice, moderate dysplasia would be excised. If a binary
system is utilized, clinicians will need to be vigilant with low-risk lesions and not ignore
them, assuming they are harmless. Some studies have shown that the malignant
transformation rate of the low-risk group can be as high as 15% [71].
A binary system has been shown previously to accurately differentiate the moderate
dysplasia group into low- and high-risk lesions and be a useful tool for predicting
progression [71]. However, a follow-up study showed the binary system improved interrater reliability but failed to accurately differentiate the ‘moderate dysplasia’ group [72].
It needs to be mentioned that the binary system still has some element of subjectivity.
Although there are specific cytological and architectural criteria that need to be identified,
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there is no specific guideline on how many elements are required to consider the criteria
positive. This could be one potential reason that binary system results are not always
replicated between studies.

5.7 Limitations of the Study
For both the manual and automated scoring methods, a component of the score was
based on the number of cells staining positive with S100A7. Straticyte evaluation utilized
‘regions of interest (ROI)’ whereas the manual scoring method evaluated the entire tissue
specimen. This could have led to some difference in the scoring between the two methods.
The ROIs Straticyte uses are 500 m diameter circles centered on staining ‘hotspots’.
This allows Straticyte to focus its analysis at specific areas of a tissue biopsy but does
not necessarily provide a global evaluation of the entire tissue sample.
One reason for scoring the lesions as we did with the manual method is because of
the field effect, which as discussed in Chapter 1, suggests that a field of tissue surrounding
the lesions of interest will be subject to genetic changes [27, 29]. In following this principle,
by evaluating the whole tissue specimen, it gives us a better idea of what is taking place at
the cellular level, not only at the region of dysplasia, but also in the surrounding tissue.
Depending on if the biopsy contained an area of surrounding normal tissue or not
could also have impacted the scoring for a case. The goal of a good excisional biopsy is to
take a surrounding region of normal tissue to ensure the entire lesion is removed. On the
other hand, incisional biopsies often do not contain any surrounding normal tissue. The
difficulty in this study is that in most cases, there was no way of confirming if the biopsy
was incisional or excisional. This could also have impacted the scoring systems, as
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incisional biopsies may be more prone to score higher than excisional biopsies using the
manual scoring method and the automated (Straticyte) scoring method may be influenced
less by the type of biopsy performed, because it is utilizing ROI hotspot locations, rather
than the entire tissue specimen.
Another possible reason for the inability to show Straticyte as a useful tool in
predicting oral dysplasia progression could be that Straticyte is designed to predict
progression over a 5-year period and not every case in our study was evaluated over a 5year period. This could be something for future studies in this area to consider.
Another limitation of the study is the small sample size. We found it difficult to
identify cases with multiple biopsies from a single site over time. Doing a multi-centre
study would help to generate more cases and could be a solution to this limitation.
Unfortunately, the attempt to obtain extended demographic and risk factor data did
not yield useful results. Performing a prospective study would help in obtaining more
comprehensive demographic data.

5.8 Straticyte Potential
The significant morbidity and mortality associated with OSCC and the low rate of
transformation of OPMD creates a significant need for an objective biomarker to aid in
differentiating high and low risk lesions [129].
The discovery of a reliable and accurate biomarker in predicting progression of
potentially malignant oral lesions would aid in clinical decision making. It would reduce
unnecessary surgery and instead direct surgery only to high-risk lesions.
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Another utility is for patients who have multiple leukoplakia throughout the mouth.
In such a case, a biomarker would allow targeted therapy only to high-risk lesions as
excising all lesions would produce significant morbidity for the patient.
Providing patients with a quantifiable risk from a diagnostic test, such as
Straticyte may provide patients incentive for reducing risk factors such as smoking and
drinking. Previous studies on the impact of lung cancer screening programs on smoking
cessation have shown that a positive (abnormal finding) CT scan can encourage cessation
[136, 137], however, persistently negative CT scans do not appear to reduce the likelihood
of smoking cessation [138], suggesting that reassurance from negative tests does not
encourage smoking. To our knowledge, there have been no studies evaluating the effects
of Straticyte on risk factor reduction, however, this is an interesting area that would be
worth exploring in future studies.
A potential disadvantage of a biomarker is that it could provide a false sense of
security. A patient that receives a report indicating/predicting a ‘low-risk’ lesion, may have
no incentive for smoking cessation or alcohol abstinence. On the other hand, a clinician
that receives a report for the same ‘low-risk’ lesion, may also not monitor the patient
adequately, may not emphasize risk factor reduction, may not perform as thorough of a
clinical examination as they otherwise should and may not arrange as strict of a
surveillance regimen as they should.
It is critical to always remember that biomarkers should only ever be used as
adjunctive information to arrive at a clinical decision. There should be no substitute for a
thorough history, physical examination, and perhaps histological assessment. The whole
context of the patient needs to be considered. A good example of this is in the detection of
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prostate cancer. A retrospective study found that digital rectal exam (DRE) was a clinically
useful tool in detecting clinically significant prostate cancer in older Caucasian men when
PSA levels were low (<2.5 ng/ml) [139]. This underscores the value of clinical examination
in addition to a quantitative biomarker assessment.
Patients with low grade lesions, such as mild dysplasia as diagnosed by
histopathology, are the ones that stand to benefit the most from a reliable objective
biomarker test such as Straticyte, as clinical decision making is likely to change the most
in patients with low-risk lesions. Currently, most patients with mild dysplasia will be
observed for clinical changes, however, an objective test suggesting that the lesion is higher
risk, will likely lead to the lesion being removed. On the contrary, a severe dysplastic lesion,
with a Straticyte score stating it is a low-risk lesion, is not likely to change the clinician’s
decision to excise this lesion.
For this reason, we think the utility of Straticyte needs to be evaluated for its
predictive ability of each grade of dysplasia independently, to determine how best to
employ the test. In other words, should the test be employed for all oral epithelial dysplasia
or only for mild epithelial dysplasia?
The risk grouping Straticyte uses could also be potentially problematic for
clinical care. A ‘low-risk’ lesion could still have a 5-year probability of cancer progression
of 18%. Although this is considered a low-risk lesion by Straticyte, for the patient sitting
in the chair, being told they have nearly a 1/5 chance of developing cancer in 5 years does
not seem like low-risk.
The other problem we noticed was that the majority of the lesions in our study were
classified as ‘intermediate-risk’ based on the Straticyte analysis. In the same way that the
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binary system of histopathological diagnosis can be a useful tool for guiding clinical
decision making, a Straticyte that was binary for only ‘low-risk’ and ‘high-risk’ lesions
would likely also be a valuable decision-making tool.

5.9 Importance of this study
The main importance of this study is to evaluate the diagnostic tool, Straticyte,
by Proteocyte AI (Toronto, Ontario, Canada). Straticyte is a diagnostic test that is now
being incorporated into clinical practice. To our knowledge, this is the first impartial study
to evaluate Straticyte’s  usefulness. Independent and unbiased studies evaluating the
work and products from industry are important to gain a comprehensive understanding of
their utility and safety.
The potential negative effects with widespread utilization if Straticyte has not yet
been validated to be both accurate and precise are: 1) unnecessary surgery occurring; 2)
relinquished surgery that should occur; 3) inappropriate follow-up schedule; and 4)
unnecessary cost to the patient; many of which could lead to the inadvertent progression of
disease.
On the contrary, if Straticyte proves to be both accurate and precise for predicting
malignant transformation for oral pre-malignant disorders, this will potentially lead to
several benefits, such as: 1) more individualized patient care; 2) less surgery on low-risk
lesions, resulting in less morbidity; 3) more surgery for high-risk lesions, leading to less
advanced disease; 4) more appropriate resource utilization, such that high-risk patients
would be seen at centers specialized in managing pre-malignant and malignant disease and
low-risk patients would be followed in the community by generalists.
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5.10 Future Studies/Work
Further work with S100A7 is required to confirm that it is a useful biomarker in
predicting progression of oral epithelial dysplasia. Additional studies should be performed
to determine if S100A7 is useful in predicting transformation from oral dysplasia to SCC,
and the expression of S100A7 in lichen planus lesions should also be evaluated to
determine if a positive correlation exists with progression.
If S100A7 proves to be an accurate and reliable marker of oral dysplasia
progression, then a prospective study comparing the predictive power of the biomarker to
the predictive power of a binary grading system using histopathological diagnosis would
be valuable. To our knowledge, this has not yet been done.
S100A7 has also been speculated to have a protective function against invasion
[100] and cyclin D1 has been suggested to be involved with invasion [134], therefore an
IHC study evaluating the simultaneous expression of S100A7 and cyclin D1 could evaluate
if decreasing expression of S100A7 is correlated with increased expression of cyclin D1 at
the same site and time.
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Chapter 6
6.0 Conclusion
Our study did not show that S100A7 was a useful biomarker for predicting
progression of oral dysplasia from a lower to a higher grade. This study also did not show
that Straticyte was useful for predicting progression of oral dysplasia alone. As
mentioned previously, this could be that Straticyte was designed to predict progression
to malignancy. We believe that more unbiased and preferably prospective studies need to
be conducted to determine the utility in predicting progression both of oral dysplasia and
from oral dysplasia to malignancy before Straticyte should be incorporated into
widespread clinical practice. In addition, the predictive power of Straticyte should be
evaluated for various grades of dysplasia as there might not be a lot of value in applying it
to all dysplastic lesions. We believe that if future studies show Straticyte to be an accurate
and reliable diagnostic test, then the main utility would be in its application to low-risk
lesions.
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Appendix
Raw Data
Manual Scoring Method (Semi-quantitative & Qualitative)
Total manual scoring of all biopsies for progressing cases of oral epithelial dysplasia
Case

Biopsy 1 Score

Biopsy 2 Score

1

7

8

2

3

4

3

5

6

4

6

4

5

5

5

6

6

7

7

5

7

8

2

6

9

5

6

10

2

3

11

3

5

12

3

3

12

Biopsy 3 Score

Biopsy 4 Score

Biopsy 5 score

6

7

8

3

13

3

6

14

0

2

15

6

6

16

8

7

17

8

6

18

6

19

7

6

20

3

6

7
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21

6

4

22

8

4

23

8

7

24

6

5

24

6

25

3

2

26

4

4

27

4

5

27

5

28

6

6

29

5

2

7

6

Total manual scoring of all biopsies for non-progressing cases of oral epithelial
dysplasia
Case

Biopsy 1 Score

Biopsy 2 Score

1

8

2

2

3

3

6

3

4

5

5

5

6

4

6

4

3

7

5

4

8

8

3

9

4

6

10

3

6

11

3

3

12

4

5

Biopsy 3 Score

2
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13

5

7

14

4

5

14

5

15

5

4

16

3

4

17

6

5

5

Total manual score of initial (and all) biopsies for control/normal/hyperkeratosis
cases
Case

Total Score

1

5

2

4

3

3

4

2

5

7

6

6

7

3

8

2

9

3

10

5

11

3

12

5

13

5

14

4

15

4

16

4

17

3
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18

2

19

2

20

4

21

2

22

2

23

3

24

3

25

2

Automated Scoring (Straticyte)
Straticyte score of all biopsies for progressing cases of oral epithelial dysplasia
Case

Biopsy 1 Score

Biopsy 2 Score

1

41.18

58.08

2

0.00

32.03

3

31.16

37.04

4

19.09

24.98

5

25.56

26.03

6

21.27

20.10

7

37.88

65.05

8

13.87

52.71

9

23.08

38.04

10

10.36

13.19

11

34.00

59.00

12

5.38

2.75

12

6.90

Biopsy 3 Score

Biopsy 4 Score

Biopsy 5 Score

45.37

55.51

19.26
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13

33.61

24.65

14

5.07

12.11

15

27.51

43.19

16

36.53

64.05

17

30.00

39.29

18

17.09

19

48.66

15.13

20

16.15

29.35

21

50.45

51.00

22

67.45

38.83

23

25.87

55.54

24

21.04

26.54

24

24.54

38.72

25

5.72

15.15

26

22.84

16.37

27

29.16

16.81

27

40.16

28

26.48

18.02

29

11.23

0.09

24.80

39.45

Straticyte score of all biopsies for non-progressing cases of oral epithelial
dysplasia
Case

Biopsy 1 Score

Biopsy 2 Score

1

65.90

26.60

2

16.00

3

11.84

12.58

4

26.18

61.02

Biopsy 3 Score
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5

23.01

23.93

6

28.99

20.34

7

9.00

12.91

8

50.42

7.68

9

11.65

19.11

10

21.64

54.00

11

42.00

50.00

12

39.00

44.42

13

50.00

53.00

14

40.00

36.20

14

48.00

15

71.00

72.00

16

32.00

40.16

17

41.75

51.00

23

55.40

Straticyte score for initial (and all) biopsies of controls/normal/hyperkeratosis
cases
Case

Controls/Normal/Hyperkeratosis

1

45.79

2

37.67

3

15.41

4

20.15

5

55.31

6

30.57

7

29.73

8

22.17

9

23.74
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10

22.92

11

17.73

12

43.15

13

40.11

14

3.31

15

18.44

16

30.89

17

50.66

18

21.54

19

24.22

20

41.15

21

20.54

22

18.06

23

51.12

24

63.33

25

18.59

Straticyte scores with associated risk group for all biopsies of progressing cases of
oral epithelial dysplasia
Case

Biopsy 1 Score

Risk Group 1

Biopsy 2 Score

Risk Group 2

1

41.18

Medium

58.08

Medium

2

0.00

low

32.03

medium

3

31.16

Medium

37.04

Medium

4

19.09

Medium

24.98

Medium

5

25.56

Medium

26.03

Medium

6

21.27

Medium

20.10

Medium

7

37.88

Medium

65.05

High

Biopsy 3 Score

Risk Group 3

Biopsy 4 Score

Risk Group 4

Biopsy 5 Score

Risk Group 5
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8

13.87

Low

52.71

Medium

9

23.08

Medium

38.04

Medium

10

10.36

Low

13.19

Low

11

34.00

medium

59.00

medium

12

5.38

low

2.75

low

6.90

low

12
13

33.61

Medium

24.65

Medium

14

5.07

low

12.11

low

15

27.51

Medium

43.19

Medium

16

36.53

Medium

64.05

High

17

30.00

medium

39.29

medium

18

17.09

low

19

48.66

medium

15.13

low

20

16.15

low

29.35

medium

21

50.45

medium

51.00

medium

22

67.45

High

38.83

Medium

23

25.87

Medium

55.54

Medium

24

21.04

medium

26.54

medium

38.72

medium

24
25

5.72

low

15.15

low

26

22.84

medium

16.37

low

27

29.16

medium

16.81

low

27

40.16

medium

28

26.48

medium

18.02

low

29

11.23

low

0.09

low

45.37

Medium

24.54

Medium

24.80

medium

55.51

Medium

39.45

medium

19.26

Medium
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Straticyte scores with associated risk group for all biopsies of non-progressing
cases of oral epithelial dysplasia
Case

Biopsy 1 Score

Risk Group 1

Biopsy 2 Score

Risk Group 2

1

65.90

high

26.60

medium

2

16.00

low

3

11.84

low

12.58

low

4

26.18

medium

61.02

high

5

23.01

medium

23.93

medium

6

28.99

medium

20.34

medium

7

9.00

low

12.91

low

8

50.42

medium

7.68

low

9

11.65

low

19.11

medium

10

21.64

medium

54.00

medium

11

42.00

medium

50.00

medium

12

39.00

medium

44.42

medium

13

50.00

medium

53.00

medium

14

40.00

medium

36.20

medium

14

48.00

medium

15

71.00

high

72.00

high

16

32.00

medium

40.16

medium

17

41.75

medium

51.00

medium

Biopsy 3 Score

Risk Group 3

23.00

medium

55.40

medium

Straticyte scores with associated risk group for all biopsies of
controls/normal/hyperkeratosis cases
Case

Controls/Normal/Hyperkeratosis

Risk Group

1

45.79

medium

2

37.67

medium
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3

15.41

low

4

20.15

medium

5

55.31

medium

6

30.58

medium

7

29.73

medium

8

22.17

medium

9

23.73

medium

10

22.93

medium

11

17.73

low

12

43.15

medium

13

40.11

medium

14

3.31

low

15

18.44

low

16

30.89

medium

17

50.66

medium

18

21.54

medium

19

24.22

medium

20

41.15

medium

21

20.54

medium

22

18.06

low

23

51.12

medium

24

63.33

high

25

18.59

low
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Initial Biopsy Only

Manual Score

Total manual score for initial biopsy of progressing cases of oral epithelial dysplasia.
Case

Biopsy 1 Score

1

7

2

3

3

5

4

6

5

5

6

6

7

5

8

2

9

5

10

2

11

3

12

3

13

3

14

0

15

6

16

8

17

8

18

6

19

7

20

3

21

6
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22

8

23

8

24

6

25

3

26

4

27

4

27

5

28

6

29

5

Total manual score for initial biopsy of non-progressing cases of oral epithelial
dysplasia.
Case

Biopsy 1 Score

1

8

2

3

3

6

4

5

5

6

6

4

7

5

8

8

9

4

10

3

11

3

12

4

13

5

14

4
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14

5

15

5

16

3

17

6

Automated Score with Risk and Area Calculation
Straticyte score, risk group and area staining for initial biopsy of progressing
cases of oral epithelial dysplasia.
Case

Biopsy 1 Score

Straticyte Risk Group

Area

1

41.18

Medium

0.54

2

0.00

Low

0.17

3

31.16

Medium

0.28

4

19.09

Medium

0.16

5

25.56

Medium

0.23

6

21.27

Medium

0.38

7

37.88

Medium

unable to assess/complex tissue

8

13.87

Low

0.03

9

23.08

Medium

0.52

10

10.36

Low

0.11

11

34.00

Medium

0.16

12

5.38

Low

0.14

13

33.61

Medium

0.14

14

5.07

Low

0.04

15

27.51

Medium

0.55

16

36.53

Medium

0.58

17

30.00

Medium

0.69

18

17.09

Low

0.40
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19

48.66

Medium

0.42

20

16.15

Low

0.02

21

50.45

Medium

0.63

22

67.45

High

0.65

23

25.87

Medium

0.58

24

21.04

Medium

0.63

25

5.72

Low

0.29

26

22.84

Medium

0.35

27

29.16

Medium

0.39

27

40.16

Medium

0.57

28

26.48

Medium

0.67

29

11.23

Low

0.34

Straticyte score, risk category and area staining for initial biopsy of nonprogressing cases of oral epithelial dysplasia
Case

Biopsy 1 Score

Straticyte Risk Group

Area

1

65.90

High

0.94

2

16.00

Low

0.01

3

11.84

Low

0.35

4

26.18

Medium

0.26

5

23.01

Medium

0.51

6

28.99

Medium

0.27

7

9.00

Low

0.18

8

50.42

Medium

0.44

9

11.65

Low

0.33

10

21.64

Medium

0.07
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11

42.00

Medium

0.14

12

39.00

Medium

0.19

13

50.00

Medium

0.34

14

40.00

Medium

0.32

14

48.00

Medium

0.73

15

71.00

High

0.59

16

32.00

Medium

0.16

17

41.76

Medium

0.64

Straticyte scoring for initial biopsy, risk category and area staining for
controls/normal/hyperkeratosis cases
Case

Controls/Normal/Hyperkeratosis

Straticyte Risk Group

Area

1

45.79

Medium

0.43

2

37.67

Medium

0.20

3

15.41

Low

0.11

4

20.15

Medium

0.01

5

55.31

Medium

0.93

6

30.58

Medium

0.57

7

29.73

Medium

0.08

8

22.17

Medium

0.03

9

23.74

Medium

0.03

10

22.93

Medium

0.17

11

17.73

Low

0.05

12

43.15

Medium

0.22

13

40.11

Medium

0.53
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14

3.31

Low

0.19

15

18.44

Low

0.04

16

30.89

Medium

0.25

17

50.66

Medium

0.28

18

21.54

Medium

0.03

19

24.22

Medium

0.12

20

41.15

Medium

0.28

21

20.54

Medium

0.01

22

18.06

Low

0.03

23

51.12

Medium

0.22

24

63.33

High

0.42

25

18.59

Low

0.06

Binary Scoring System
WHO binary scoring of initial biopsy for non-progressing cases.
Case

Diagnosis

Binary Score MD Binary Score LM

1

moderate to severe dysplasia

high

high

2

Mild atypia with hyperkeratosis

low

low

3

Mild to moderate dysplasia

low

high

4

moderate to severe dysplasia

high

high

5

moderate to severe dysplasia with focal CIS

high

high

6

mild to moderate dysplasia

high

high

7

Verrucous hyperplasia with early verrucous carcinoma

no grade

no grade

8

mild dysplasia

low

high

9

moderate dysplasia

high

high

10

hyper-orthokeratosis with mild dysplasia

high

low

11

mild dysplasia

low

low
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12

moderate dysplasia

high

high

13

mild dysplasia

low

low

14

amalgam tattoo

no grade

no grade

15

mild to moderate dysplasia

high

low

16

Mild to moderate dysplasia

high

high

17

verrucous hyperplasia with moderate epithelial dysplasia

high

high

18

moderate dysplasia

high

high

19

mild dysplasia

high

high

20

mild dysplasia

low

low

21

mild dysplasia

low

high

22

severe dysplasia

high

high

23

mild to moderate dysplasia

high

high

24

moderate dysplasia

high

high

25

mild dysplasia

high

high

26

mild dysplasia

high

low

27

mild dysplasia

Unable to locate

Unable to locate

27

mild dysplasia

Unable to locate

Unable to locate

28

mucositis with hyperorthokeratosis

high

low

29

severe dysplasia

high

high

WHO binary scoring of initial biopsy for non-progressing cases
Case

Diagnosis

Binary Score MD

Binary Score LM

1

moderate to severe dysplasia

low

low

2

mild dysplasia

low

low

3

CIS

high

high

4

moderate dysplasia

high

high

5

high

high

6

moderate to severe dysplasia
hyperparakeratosis with chronic
mucositis

low

low

7

moderate to severe dysplasia

high

high
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8

moderate dysplasia

high

high

9

moderate dysplasia

high

high

10

mild dysplasia

high

low

11

mild dysplasia

low

low

12

mild dysplasia

13

low
lichenoid mucositis/arch
atypia

14

mild dysplasia
hyperkeratosis with mild epithelial
atypia and chronic mucositis
hyperkeratosis with mild epithelial
atypia

low
lichenoid mucositis/arch
atypia
low
hyperkeratosis/chronic
mucositis

low
hyperkeratosis/chronic
mucositis

15

mild dysplasia

low

low

16

mild dysplasia

low

low

17

mild dysplasia

Unable to locate

Unable to locate

14
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